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O tratamento de Radioterapia pretende atuar contra uma das principais causas de morte mundial-
mente sentidas, o cancro. Esse tratamento consiste em irradiar o tecido danicado com elevada
dose de radiação, de modo a cessar a proliferação das células cancerígenas. O mesmo é realizado
com a máxima de tentar proteger o melhor possível o tecido envolvente, de modo a minimizar
os efeitos secundários do tratamento no paciente.
Ao longo dos últimos anos têm-se vericado inúmeros desenvolvimentos e mudanças na
forma como a Radioterapia se procede, devido ao grande crescimento tecnológico ocorrido. Tendo
sempre em mente o objetivo de minimizar a dose entregue no tecido saudável, novas técnicas de
tratamento foram desenvolvidas, como por exemplo, IMRT (Intensity-Modulated Radiation Ther-
apy) e VMAT (Volumetric-Modulated Arc Therapy), as quais permitem a irradiação mais precisa
do tecido cancerígeno, através da sua conformação por parte das folhas, um constituinte inte-
grante do acelerador. Também foram desenvolvidas novas técnicas de imagem que melhoraram
tanto os processos de planeamento como o tratamento em si. Com o aparecimento de novos,
precisos e ecazes softwares e sistemas, também o planeamento do tratamento mudou. Assim,
em resposta às necessidades requeridas pela entrada de novos e complexos modos de tratamento
e sistemas utilizados, o processo de controlo de qualidade tornou-se essencial no planeamento
do tratamento. Com este processo pretende-se assegurar que o tratamento seja administrado
ao paciente da forma mais segura e precisa. O controlo de qualidade em IMRT, e neste caso,
especíco a cada paciente, consiste numa medição do plano do paciente previamente realizado
recorrendo-se aos sistemas de planeamento próprios. Esta medição simula o tratamento e re-
quer sistemas especícos para a sua realização. Posteriormente procede-se a uma comparação
do que foi medido com o planeado, de modo a vericar se existem erros no plano e se este pode
ser ou não aprovado para o tratamento. Como método de análise da distribuição de dose quer
no plano medido quer no planeado, é utilizada a análise gama que combina dois critérios, o de
diferença de dose e o de distância, para calcular as diferenças existentes entre a distribuição de
dose desses dois planos. No entanto, têm-se vericado alguma incoerências e falta de precisão
por parte desse método, questionando-se a sua capacidade para estimar a presença de efeitos
negativos clinicamente relevantes e erros no plano de tratamento do paciente.
Na Fundação Champalimaud, o processo de controlo de qualidade especíco a cada paciente
em IMRT é realizado diariamente, utilizando a análise gama como método de avaliação da dis-
tribuição de dose e o ArcCHECK, desenvolvido pela Sun Nuclear Corporation, como sistema de
medição de dose.
Este estudo foi efetuado de modo a melhorar o processo de controlo de qualidade realizado na
Fundação Champalimaud. Esse consistiu no teste de um software, 3DVH, também desenvolvido
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pela Sun Nuclear Corporation, que permite avaliar a distribuição de dose recorrendo à análise com
DVH, Dose Volume Histogram, o método promissor e que pretende substituir a análise gama no
processo de controlo de qualidade. DVH consiste num gráco que relaciona a dose entregue por
volume (em percentagem) de cada estrutura analisada.
Para cumprir o principal objetivo deste estudo, foram feitos dois testes: um com campos
quadrados abertos, e o segundo com planos de tratamento de pacientes. Seis planos de pacientes
foram usados, cinco de cancro da mama e um de cancro da próstata. Todos os planos foram
calculados no sistema de planeamento, Monaco.
Em ambos os testes foram usados planos com erros, ou seja, foram introduzidos erros nas
folhas e nas unidades monitor (uma medida de calibração do acelerador associada à dose). Os
primeiros alteram a posição das folhas, abrindo ou fechando as mesmas, tendo em conta o erro
introduzido. Já os segundos erros alteram a quantidade de unidades monitor entregues no trata-
mento, reduzindo ou aumentando o seu número, tendo também em conta o erro introduzido. Rel-
ativamente aos erros nas folhas, foram introduzidos erros sistemáticos e aleatórios. Os primeiros
consistem na mudança sistemática e simétrica da posição das folhas, ou seja, todas fecham ou
todas abrem. Nos erros aleatórios as folham movem-se aleatoriamente, não se sabendo a priori
que posição essas podem tomar. Foram introduzidos erros sistemáticos de ±0.5, ±1, ±2 e ±3 mm
e erros aleatórios com desvio padrão de 1, 2, 3, 4 e 5 mm. Relativamente aos erros nas unidades
monitor, foram introduzidos erros sistemáticos de ±2 e ±4%.
De modo a perceber se os softwares estão a efetuar as análises de uma forma precisa e se
os sistemas de medição estão a adquirir dose de uma forma ecaz, foram realizadas predições
para ambos os testes. No teste com campos quadrados abertos, ou seja, com planos mais simples,
foi possível realizar as predições tanto para os dados dos erros nas folhas como para os dados
dos erros nas unidades monitor. Enquanto que, para o teste com planos de pacientes apenas
foram feitas predições para os dados dos erros nas unidades monitor, pois estes planos são mais
complexos na forma como o plano é irradiado.
As medições de todos os planos com e sem erros foram efetuadas recorrendo-se ao acelerador
Synergy, da Elekta, e aos sistemas de aquisição de informação dosimétrica, ArcCHECK e EPID
(Electronic Portal Imaging Device). Utilizou-se o ArcCHECK, pois é o sistema utilizado na fun-
dação e o que fornece os dados de medição compatíveis e necessários para realizar a análise em
3DVH. No caso do EPID, este, nós últimos anos, tem mostrado grandes capacidades dosimétri-
cas e muitas vantagens por ser um sistema sicamente ligado ao acelerador e já integrante no
processo de controlo de qualidade em alguns institutos. Na fundação encontra-se em investi-
gação, na tentativa de ser implementado, por isso também entrou para este estudo, de modo a
ser comparado com o ArcCHECK.
As análises gama e com DVH foram feitas recorrendo-se aos especícos softwares de cada
sistema de medição, PreDose, pdapp e pdDVH que usam os dados provenientes das medições
com EPID e SNC e 3DVH que usam os dados provenientes das medições com ArcCHECK.
Os resultados relativos aos testes feitos com campos quadrados abertos mostraram que os
sistemas foram capazes de detetar a presença dos erros nas unidades monitor tanto através da
análise gama, como da análise usando DVH. No caso da deteção dos erros nas folhas, o 3DVH
mostrou reduzidas capacidades para o fazer, ao contrário dos softwares de análise respetivos
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ao EPID, tanto para a análise gama como para a análise usando DVH. Foram observadas algu-
mas faltas de correlação entre a análise gama e a análise com DVH. Percebeu-se ainda que os
erros maiores causam também maiores perturbações, neste caso, menores gamma passing rate,
parâmetro de análise calculado pela análise gama, maiores desvios entre os DVHs de referência e
os de medição e maiores valores de diferença de dose média. Pelas análises dos DVHs também se
conseguiu perceber com maior clareza em que estruturas os efeitos eram mais evidentes e que os
erros negativos causavam uma redução da dose entregue ao paciente e os positivos um aumento
dessa mesma dose.
No caso dos resultados obtidos a partir dos testes com planos de pacientes, esses também
mostraram algumas faltas de correlação entre a análise gama e a análise com DVH. Nestes testes
a análise com DVH apenas foi realizada com o 3DVH, pois não foi possível realizar medições
com erros em planos de pacientes. Nestes testes o 3DVH mostrou-se bastante ecaz em ambas as
análises, destacando-se principalmente na análise com DVH, pois fornece bastante informação
relativa à distribuição de dose no paciente. No entanto, devido aos resultados menos bons na
deteção de erros nas folhas, as suas análises podem não ser as mais seguras. No caso na deteção
de erros nas unidades monitor, tal como no teste dos campos quadrados, o 3DVH conseguiu
detetar os erros em aproximadamente todos os planos analisados.
Em suma, o 3DVH parece ser uma boa opção a implementar no processo de controlo de
qualidade da Fundação Champalimaud, tendo em conta que é um software compatível com o
sistema de medição usado, essencialmente para efetuar a análise com DVH, a qual mostrou ser
clinicamente mais eciente e relevante do que a análise gama. No entanto, o 3DVH necessita
de algumas melhorias. As faltas de correlação visíveis entre a análise com DVH e a análise
gama mostram que este último método pode esconder erros relevantes, enquanto o tratamento é
aprovado pelo mesmo. Como mencionado anteriormente, a análise com DVH, principalmente no
3DVH, fornece muita informação relevante e permite ter uma melhor noção das zonas afetadas
pelos erros e com que intensidade estas são perturbadas, analisando valores especícos de dose,
como por exemplo, a dose máxima, a dose média, a dose que afetou 95% do volume, entre outros.
Pretende-se ainda perceber quais são os melhores valores de restrição de dose a analisar. O EPID
também se mostrou muito eciente e ecaz na deteção dos erros, e quando este for clinicamente
aceite, poderá ser a melhor opção para realizar a controlo de qualidade especica a cada paciente
em IMRT, tendo em conta a sua geometria (está acoplado ao acelerador) e resolução.





In the last years, great developments in radiotherapy took place both in technology and in treat-
ment techniques. An example of this is the Intensity-Modulated Radiation Therapy (IMRT),
whose emergence changed the way treatment planning is performed. As a consequence, patient-
specic quality assurance (QA) became essential in the treatment planning. This makes sure that
the treatment is carried out as planned and it assures the quality of the treatment and safety of
the patient. The QA consists in comparing the planned and measured dose distributions. Gamma
analysis is the most common mathematical method used for dose comparison. It compares two
dose distributions, reference dose and evaluated dose, by combining dose and distance criteria.
However, gamma analysis has demonstrated incoherencies, poor accuracy in estimating the er-
rors and poor correlation with clinically relevant dose deviations.
This study was performed in order to improve the patient-specic QA process carried out
in Champalimaud Foundation. It consisted in testing a new software, 3DVH, that uses an alter-
native, Dose Volume Histogram (DVH) analysis to compare measured and planned doses. This
method intends to replace the gamma analysis in QA.
To this end, two tests were performed, the rst with open square elds plans and the second
with patient plans. In both tests, MLC and MU errors were introduced in the plans, changing the
leaves positions and the monitor units quantity used for the treatment, respectively. The mea-
surements were carried out with the The ArcCHECK and the Electronic Portal Imaging Device
(EPID) to measure the dose distribution. ArcCHECK is the device used in Champalimaud Foun-
dation for QA measurements, and the EPID is the device that has been demonstrating accurate
dosimetric capabilities and is currently in research in Champalimaud Foundation. The analysis
was made using specic software: PreDose, pdapp and pdDVH for the EPID data, and commercial
SNC and 3DVH for the ArcCHECK data. Thus, the reference and the measured dose distributions
were compared using both gamma analysis and DVH analysis, and the results were compared
with predictions previously calculated, in order to verify if there is a correlation between both
methods and to test the accuracy of the systems to detect the errors.
In the square elds test, unlike 3DVH, EPID showed more sensitivity to estimate the eects of
the MLC errors in the plans, mainly in the DVH analysis. All the systems detected the presence of
the MU errors in the gamma and in the DVH analysis. Lack of correlation was observed between
the gamma analysis and the DVH analysis, i.e. the gamma analysis can provide wrong results
and hide relevant errors, while the treatment is approved. On the other hand, the DVH analysis
provides more and clinically relevant information about the eect of the errors in the structures.
In the patient plans, the DVH analysis was just performed by the 3DVH and it showed sig-
nicant accuracy in its performance for detecting MU errors. For MLC errors, its results are not
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very reliable, due to the lesser results obtained in the square elds test. All the systems detected
the presence of the errors in the gamma analysis. However, a lack of correlation between the
DVH analysis and gamma analysis was also observed.
This study proved that the gamma analysis is a limited method, with incoherencies and that
it is not a good method to estimate eects of the errors. On the other hand, the DVH analysis
showed accuracy and eciency in dose distribution evaluation, providing general (of all treat-
ment) and individual (of each structure) clinically relevant information. Thus, 3DVH is a good
system to be implemented for the DVH analysis. However, should EPID be clinically accepted,
it is the best option, taking into account its geometry, performance and resolution.
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Cancer remains among the leading causes of death worldwide. According to recent statistical
studies, this disease appears as the second main cause of death after cardiovascular disease, caus-
ing 8.2 million deaths globally with 14.9 million new cases in 2013 [1]. This disease, also dened
as malignant tumours and neoplasms, is the rapid appearing and growth of abnormal cells, with
unlimited proliferative potential, that grow beyond their usual boundaries and spread to other
organs, creating metastases [2]. In Europe, in 2012, there was an estimate of 3.45 million new
cases of cancer and 1.75 million deaths from cancer. In Portugal, in the same year, 491.8 hundred
cases of cancer were reported, 241.1 hundred of which resulted in death [3].
Radiotherapy (RT) appeared in order to reduce the number of cancer deaths, being one of the
major treatment methods for cancer, along with surgery and chemotherapy. The aim of radio-
therapy is to, noninvasively, stop the proliferation of the cancer cells, preventing its continuous
spread along the body. This is achieved by radiating the tumour tissue, i.e. the target region,
with high-energy radiation. It has been assured that the surrounding normal healthy tissue will
be spared as much as possible to prevent damage in the body. Irradiation is done by using ex-
ternal beam radiotherapy (EBRT) or brachytherapy, which will be explained in more detail later
on. The eect caused in the tissue depends on the types of the types of radiation particle beams
used, each of which have dierent interactions with the tissue. Megavoltage X-rays (photons),
electrons and protons are the most commonly radiation types used [4, 5, 6].
RT was developed in the beginning of the century XX and has been subject to a number of
technological innovations. Despite the fact that radiotherapy is one of the most used treatments
of cancer, it is not perfect and complications may happen, such as healthy tissue aected or
overdose administered. The research evolved aiming to prevent and overcome these problems,
rendering the treatment more ecient and accurate.
This growth and development of radiotherapy was achieved by the rapid advance of new,
high precision and improved technology, signicantly changing the way radiotherapy is planned
and carried out. In the image eld, various procedures have been used (computed tomography,
positron emission tomography, magnetic resonance imaging, ultrasonography), which are help-
ful for the treatment and which also belong the radiation therapy planning process. New and
more sophisticated planning software has also been coming about. Consequently, there was
a signicant development of complex and accurate treatment planning procedures. In case of
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delivered dose techniques of external beam radiotherapy, a growing interest in hypofraction-
ated treatments was observed. These types of treatment allow for a higher dose delivery per
fraction, which therefore diminishes the number of fractions needed. Intensity-Modulated Ra-
diation Therapy (IMRT) and Volumetric-Modulated Arc Therapy (VMAT) are the most recently
used techniques. They make use of multileaf collimators (MLC) which improve the eciency of
treatment delivery, replacing conventional blocking [7]. The Electronic Portal Imaging Device
(EPID) was also an important technological innovation, because it allows to obtain easily and
rapidly information about dose delivery in two or, preferably, three dimensions [5]. All these en-
hancements in radiotherapy imply a new way to perform Quality Assurance (QA) process, which
evaluates the accuracy of the treatment and consequently the dose delivery in the patient with
as few errors as possible. It consists in comparing a calculated dose distribution, using treatment
planning system (TPS), to a measured dose distribution in a phantom, applying the patient plan
to the phantom [6, 8].
Our project intends to improve the way patient-specic IMRT QA is performed. In the Cham-
palimaud Foundation, the QA is carried out with a phantom, ArcCHECK, and gamma analysis,
as the metric tool, to perform dose distribution comparisons. However, this metric tool shows
some inconsistencies in its performance. Thus, the commercial 3DVH software was developed,
which allows to carry out patient-specic QA by analysing dose per organ volume with Dose
Volume Histogram (DVH), a more ecient and informative method for the patient’s dose deliv-
ery analysis. The main goal of this project is to test this method and software with ArcCHECK, as
well as the promising device to perform quality assurance in pre-treatment, the aforementioned
EPID. This test has been carried out comparing measured and planned doses distributions using
gamma analysis and DVH analysis, in order to verify whether or not there is a correlation be-
tween both methods. Square eld plans and plans from breast and prostate were used to measure
dose distribution. MLC and monitor unit (MU) errors were introduced in the plans in order to
check the accuracy of both systems, ArcCHECK and EPID, to calculate DVHs, comparing these
plans with error-free plans.
This dissertation describes the project developed in Foundation Champalimaud during nine
months. It is divided in ve chapters, in which all the information regarding the evaluation
and implementation test of the 3DVH is presented. Chapter 1 is a general introduction to the
dissertation, where the project and its aim and contents are presented. Chapter 2 reports the
background of the project, presenting some concepts about some techniques of radiotherapy
and previous studies and approaches regarding QA in IMRT. Chapter 3 describes the systems,
software, methods and procedures used in this work to acquire and analyse the dose data. Chap-
ter 4 shows the main results obtained and their specic discussion. Finally, Chapter 5 summarizes





2.1.1 Principles of Radiotherapy
Radiotherapy, or radiation therapy, is one of the major treatments used in cancer treatment, be-
ing one of the three main therapies used. In surgery the tumour is removed; in chemotherapy
chemical substances are introduced in the blood ow to eliminate the cancer cells; and in ra-
diotherapy the tumour cells are killed using ionizing radiation. Depending on the cancer, it is
possible to combine dierent therapies, in order to improve the treatment, or to use only one
therapy.
The main goal of radiotherapy is to deliver a radiation dose to the tumour while sparing the
normal tissue and possible surrounding organs at risk (OAR). The ionization radiation causes
irreparable genetic damages in the tumour cells, killing them directly or causing cell apoptosis. In
other words, when damages in the DNA structure of a cell occur, its reproduction is interrupted,
causing cancer cells to die and, subsequently, the tumour stops growing. When the radiation
dose is delivered to the patient’s tissue, the absorbed dose varies while beam penetrates in depth.
This variation depends on many parameters, such as beam energy, depth, eld size and source
distance [9].
Each cancer has inherently dierent radiation sensitivity, determining how to proceed in dose
delivery process. Therefore, there are two types of radiation delivery, external beam radiotherapy
and brachytherapy. The rst one is regularly used and utilises high energy beams of ionization
radiation of photons, electrons or protons to destroy the tumour cells inside the human body. The
dose is delivered by a linear accelerator, which can generate radiation beams from dierent angles
by rotating the gantry. Photon therapy is used in deep tumours, being able to penetrate deep into
the body while sparing the skin; electron therapy is used for supercial treatments, providing a
high dose to a few centimetres depth from the skin surface avoiding dose delivery beyond that;
and proton therapy delivers energy with extreme precision, therefore limiting unwanted dose.
The external beam radiotherapy method will inevitably cause damage of surrounding healthy
tissue beyond tumour tissue. In order to overcome this negative point, several strategies are
applied in clinical practice, improving the treatment as much as possible. As to the second type
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of radiation delivery, brachytherapy, sealed radiation sources are temporarily or permanently
placed into the tumour. As the sources are very close to the damaged tissue, their reach is limited,
so the dose is delivered to the tumour in a precise way, sparing surrounding tissues. However,
this method is invasive and less homogeneous, being specially used for smaller tumours [10, 11].
The ionising radiation, when interacting with the human tissue, causes some damage. There
are physical eects, when radiation absorption in tissues leads to ionization and excitation; chem-
ical eects result in breakage of chemical bonds and in generation of free radicals, because dam-
aged atoms and molecules will react with other cellular components; biological eects lead to
enzymatic reactions that act on residual chemical damage and the damage in the DNA that is
not repaired and it leads to cell death; nally there are also clinical eects regarding delivered
radiation process [11].
2.1.2 External Megavolt Photon Beam Radiotherapy Treatment
External megavolt photon beam radiotherapy is one of the most frequently used techniques
to dose delivery treatment, as previously described (subsection 2.1.1). It uses photons of high
energies to treat deep-seated tumours. Photons are produced by linear accelerators (LINACs).
Electrons are generated and accelerated to high kinetic energies from 4 to 25 MeV using non-
conservative microwave RF elds, in the LINAC, and then they collide with a tungsten target and
lose kinetic energy, resulting in photon beam. It can be used for treatment after its additional col-
limation and optional ltering [6, 12]. A typical LINAC, represented in Figure 2.1, is composed
of gantry, stand, modulator cabinet, treatment couch and control console. However, there are
signicant dierences between commercial machines, depending on the goal of the treatment
made using the respective system [12, 13].
Figure 2.1: Illustration of LINAC setup and its components. The intern components are not illustrated in the gure.
Adapted from [14].
The gantry is responsible for delivering the photon energy beam to a patient’s tumour, ro-
tating around him. It is composed of an electron gun, where the electrons are produced and
then injected into the accelerator structure; of an accelerator structure, where the electrons are
4
2.1. Radiotherapy
accelerated; and of a treatment head, which is composed of certain components (bending mag-
net, primary and second collimators, attening lter (FF) and scattering foil) designed to shape
and monitor the treatment beam, obtaining a more uniform beam. As to the stand, it contains
the set of systems (klystron or magnetron, waveguide, circulator and water-cooling system) that
drives the linear accelerator, generating and guiding the electromagnetic waves to the acceler-
ator guides. The modulator cabinet contains components that distribute and monitor primary
electrical power and high-voltage pulses to the klystron or magnetron. The control console is
responsible to monitor and to control the LINAC [13].
A major limitation to the ecacy of radiotherapy treatment is the production of undesirable
complications caused by the irradiation of healthy tissue. Many organs are sensitive to radiation
damage, thus special attention must be given and there must be alternatives to overcome this
drawback. Beam shaping is a prerequisite and one of the options to take into account, in order
to obtain dose distributions that conform to the tumour volume while sparing neighbouring
health tissue. A conventional treatment machine shapes X-ray elds through a set of two pairs
(upper (Y) and lower (X)) of dense metal collimators, jaws (or second collimator), built into the
machine that produces rectangular beams, limiting the size of the treatment eld. The jaws can
open from 0 cm to the maximum eld size of about 40 cm, or a little less. MLC is the most
recent component of LINAC for beam shaping, replacing beam blocks on account of the several
inherent disadvantages they presented, such as their manufactore, handling and storage is labour
intensive and resource consuming. The MLC is located inside the LINAC, between both upper
and lower jaws, and it consists typically of a set of 80 to 160 metallic leaves arranged in pairs
with 0.25 to 1.0 cm wide. MLC movements are tracked by Y and X jaws in a horizontal and
vertical direction, respectively. They can be positioned individually to shape the beam aperture
to conform to the tumour, blocking some fraction of the radiation beam, in order to reduce the
dose delivered to surrounding healthy tissue [6, 7].
The photon beam ia a bremsstrahlung beam. As such, its distribution in the MeV energy
range demonstrates both an energy and intensity variation of the primary photon uence with
emission angle. To compensate for this eect, there are some accelerators with FF placed in the
treatment head, located between the primary collimator and ion chamber, although this cong-
uration can vary with the manufacture. FF modies the distribution of photons, providing an
almost uniform dose distribution at specic treatment depth, as shown in Figure 2.2. These l-
ters consist of conical shaped pieces of metal, typically made of materials such as iron, copper
or tungsten, and are specic to each particular energy [15, 16]. FF was important to compensate
dose distribution eects. However, FF scatter photons are one of the major sources of radiation
scatter in the treatment head and can lead to higher doses outside the treatment eld [16, 17].
In response to this, advanced treatment techniques, such as IMRT and VMAT, where varying
uence pattern across the beam is delivered, have stimulated the increasing interest in oper-
ating linear accelerators in a atting lter free (FFF) mode. Its inverse planning tools are able
to handle unattened beams. Besides reducing radiation scatter, removal of the attening lter
contributes to the increase of the dose rate, which is benecial for the patient due to a reduction
of the treatment duration, as well as of the leaf transmission, leakage radiation and out of eld
doses. Removing FF also provides improved accuracy in dose calculations [17].
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Figure 2.2: Illustration of radiotherapy treatment with (a) and without (b) attening lter, respectively, and beams
dierences. Adapted from [18].
The EPID is another important component of modern LINACs. It allows to obtain images
from the high energetic MV photon beam that exits from the patient during treatments. These
images can be used for patient set-up verication or detection of organ motion and also for
dosimetric verication of treatment, which is called portal dosimetry [6].
The treatment is often performed in a fractioned schedule, where the total dose is delivered,
normally in 30 to 40 fractions, ve times a week, typically lasting 5 to 8 weeks with a small (1.8 to 2
Gy) dose per fraction [12, 19]. However, with the improved accuracy in the way how radiotherapy
is performed, a new mode to deliver dose to the patient was developed, hypofractionation. This
delivers dose in a smaller number of fractions than in a conventional treatment. So the method
can also deliver higher fraction doses, commonly measuring between 2 Gy and 8 Gy, as compared
with conventional radiotherapy. Thus, this process exposes a tumour to a higher dose of radiation
in a shorter period of time, sparing surrounding tissues, shortening the time of treatment and
increasing its eciency in destroying tumour cells [20, 21].
2.2 Dose Delivery Techniques
2.2.1 Conventional and Three-dimensional Conformal Radiotherapy
In the last years, progress was made in the way treatment is performed using radiation, in the
devices and equipment used and in the treatment planning, the main goal being the reduction
of the dose delivered to the normal tissue. Conventional radiotherapy denes the area to be
treated in relation to bony landmarks. Multiple overlapping beams are then used to create a
brick-shaped central region of high dose distribution. This method is simple and quick, but
results in the irradiation of signicant healthy tissue volume [22].
Three-dimensional Conformal Radiotherapy (3D-CRT) was then implemented, with the in-
troduction of CT scanning, which improved the accuracy of dening and dierentiating both
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the tumour and organs at risk. In this technique, the beams of radiation used in treatment are
shaped to match the tumour, allowing accurate dose conformity to irregular shapes. As its name
indicates, this technique is based on 3D anatomic information, 3D target localisation, 3D treat-
ment planning and 3D dose delivery techniques. 3D-CRT uses the image targeting information
from CT, or other imaging techniques, to focus precisely on the tumour avoiding the healthy sur-
rounding tissue, improving conformity of the radiation. Thus, it is possible to use higher levels
of radiation in treatment, while sparing as much as possible the normal tissue. However, in order
to treat with these high doses, it is necessary to further reduce the target volume irradiated. This
would only be possible with the introduction of IMRT [12, 22, 23].
The treatment planning of the 3D-CRT is achieved with standard forward planning tech-
niques, which design uniform intensity beams shaped to the geometrical projection of the target.
In this planning process, beam arrangements are tested by trial and error, until a satisfactory dose
distribution is produced. This is done manually, not via mathematical algorithms and computer
software [12, 13].
Figure 2.3 shows the dierence between three therapies.
Figure 2.3: Illustration of the three therapies and their dierences: (a) conventional radiotherapy, where dose is deliv-
ered using brick-shaped elds with additional blocks and wedges, (b) three-dimensional conformal radiotherapy with
multileaf collimator, but without intensity-modulation, and (c) intensity-modulated radiation therapy with multileaf
collimator and intensity-modulation with shaped eld [24].
2.2.2 Intensity-Modulated Radiation Therapy
Intensity-modulated radiation therapy is one of the most important advances in radiotherapy of
the last decades, being one of the results of the great developments in technology and health
science. It is the advanced form of three-dimensional conformal radiotherapy. There is an exten-
sive and ongoing world-wide research on the applications and improvements of this technique
[22]. The introduction of IMRT changes the way how treatment planning occurs. Here inverse
planning is used (to be further exposed), which utilises, in addition to beam shaping, intensity
modulated beams to improve target dose homogeneity and to spare organs at risk [12].
An ideal radiotherapy treatment should deliver a high dose of radiation to the tumour tissue,
causing minimal damage to the surrounding tissue. Intensity modulation with treatment beams
can deliver radiation more precisely to the tumour, allowing more normal tissue to be spared
than other techniques. This provides the possibility of both reducing toxicity and increasing the
delivered dose to the target volume, improving tumour control. Comparing to 3D-CRT, IMRT
diers in the existence of non-uniform intensity of the radiation and in the appearance of com-
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puterised inverse planning [22]. It was put forward in 1982 by Brahme et al. [25]; it describes how
a rotational technique with a simple idealised uence modulation can irradiate uniform dose. In
1988 Brahme [26] developed a concept of creating uence proles from the required dose dis-
tributions. These approaches were also important for the introduction of the inverse planning
concept, where, unlike in forward-planning approach, the starting point is the required dose
distribution and the goal is to nd a non-uniform uence map that can produce it [24, 27].
The goal of IMRT is to shape the radiation dose to avoid or reduce exposure of healthy tissue
and limit side eects of treatment while delivering a therapeutic dose to the cancer. This is pos-
sible because it allows the modulation of the intensity or uence of each radiation beam, so each
eld can have one or many areas of high intensity radiation and any number of lower-intensity
areas within the same eld. Thus, it allows a greater control of the dose distribution in the target.
The beam is manipulated so that when all the radiation delivery is considered, the dose conforms
closely to the tumour or target volume within the patient. Unlike in conventional radiotherapy,
IMRT is a xed-beam treatment and uses MLC to modify both shape of the beams and the inten-
sity distribution within each beam, instead of using blocks and wedges. With the introduction
of MLC in the treatment, conforming the radiation to the target shape became signicantly eas-
ier, more than with 3D-CRT. These leaves can move smoothly in and out of the treatment eld
during a short period of time [23, 28, 29].
There are two types of IMRT, the step-and-shoot IMRT, or segmented MLC IMRT (SMLC-
IMRT), and the dynamic MLC IMRT (DMLC-IMRT), both presented in Figure 2.4. In the rst
one the leaves remain xed during irradiation and the beam is turned o between consecutive
MLC shapes. Which means, for each beam orientation, several dierent MLC-shaped elds are
created and a modulated eld intensity is achieved by summing all the elds. In the second one,
the leaves are in continuous motion while the beam is on, moving in and out of the eld to
create the desired dose distribution. The intended intensity of radiation to the specied point is
obtained due to existence of variation of the speed and distance between leaves [22, 29].
Figure 2.4: Illustration of two types of IMRT: (a) Step-and Shoot IMRT and (b) Dynamic IMRT. These methods use
MLCs to create intensity distributions. In the rst one, the beam is o during leaf motion, whereas in the second one
radiation is delivered during leaf motion. Adapted from [29].
Thus, this technique can improve target conformity and it also can increase normal tissue
sparing and can enable dose escalation. However, IMRT presents some drawbacks, such as the
fact that it increases time needed for target and organ outlining, it needs extensive quality as-
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surance process, it increases machine treatment time, as well as planning time and total body
irradiation dose [22, 29].
The emergence of this technique has also changed the way treatment planning is performed.
Before IMRT, radiation treatment was performed employing a forward planning process, during
which the beams were manually set by physicists, choosing its number, shape and orientation
and the wedges were also congured, in order to calculate dose distribution. In the case of the
IMRT, inverse planning is used. It automates IMRT with an optimisation computer program,
which determines the position, shape and intensity of the radiation beams in order to produce the
required, ideal and most favourable 3D dose delivery, specifying the plan in terms of the tumour
dose and normal structure dose limits. The computer system adjusts the beam intensities to nd
a conguration that best matches the required treatment plan. This process does not dependent
as much on the geometric parameters as it does on the specication of volumes of tumour targets
and sensitive structures, as well as on their dose constraints [22, 23, 24, 28].
2.2.3 Volumetric-Modulated Arc Therapy
Volumetric-modulated arc therapy is a recent and widely used method of delivering intensity
modulated elds. It is a singular technique of IMRT, developed from the Intensity Arc Modulated
Therapy (IMAT) that allows a treatment to be delivered in one or more dynamically modulated
arcs. IMAT, proposed in 1995 by Yu [30, 24, 31], is similar to VMAT in that radiation is delivered
while the gantry rotates around the patient and in every gantry rotation one intensity level is
delivered from all angles. However, in the IMAT the dose rate and gantry speed are held constant,
meaning it is not possible to change rate dose in each arc, which happens in the VMAT. Intensity
modulation is achieved by delivering radiation over multiple gantry arcs. To increase dose level
resolution, it is necessary to increase the number of arcs, which increases the treatment time
[23, 27, 29].
VMAT diers from IMRT, as it is possible to see in Figure 2.5, in the fact that the radiation
is delivered while the gantry rotates around the patient in one or more 360◦ maximum gantry
rotation arcs, making it a faster method than IMRT. The dose is shaped using three important
variables: MLC shape, gantry rotation speed and dose rate [27, 29].
Figure 2.5: Illustration of image acquisition of treatment using (a) VMAT and (b) IMRT therapies. In the rst one,




2.3 Main Radiotherapy steps
In order to provide a better treatment for the patient, there are several factors to take into ac-
count and some procedures to follow. The main steps in radiotherapy, presented in Figure 2.6,
are: evaluation consultation, patient positioning and immobilisation, image acquisition, target
volume denition and organ delineation, dose planning, quality assurance, treatment delivery
and clinical monitoring. There are some signicant dierences between planning and treatment
delivery processes.
Figure 2.6: Schematic representation of the main steps in Radiotherapy.
2.3.1 Evaluation
The rst step in radiotherapy is to make an evaluation of the patient, in order to understand the
disease stage and dene which treatment will be used and its aim. Afterwards, it is necessary to
obtain images of the patient and delineate the targets and normal tissues on those images.
2.3.2 Pre-treatment: Treatment Planning
Pre-treatment consists in a set of processes carried out before treatment, in order to guarantee
and provide the best treatment possible for the patient. It includes procedures such as immobil-
isation of the patient, image acquisition, target volume denition, dose prescription and quality
assurance.
Immobilisation
It is necessary and important to the accuracy of the treatment that the position and anatomy of
the patient coincide exactly with the geometry images acquired during the planning [9].
The treatment position depends on the location of the tumour. Several individual immo-
bilisation techniques are used, such as simple immobilisation accessories (of members, of neck,
amongst others) and of the thermoplastic masks. All these techniques allow to choose the best
and most comfortable position for the patient. Skin marks are created on the patient for reposi-
tioning in the treatment. The position and immobilisation of the patient is, therefore, important
during all the treatment process [9].
Imaging Acquisition
Imaging acquisition process allows for volume delineation of target organs and organs at risk,
identifying the tumour and the normal tissues to be avoided. The image is acquired for each
patient during the treatment position step.
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There are many types of imaging acquisition. Computed tomography (CT) was the primary
and standard imaging modality used for target delineation and dose calculation. However, other
imaging modalities such as magnetic resonance imaging (MRI), positron emission tomography
(PET) and Single-Photon Emission Computed Tomography (SPECT) can also be used. CT is
widely and easily available, geometrically accurate and provides quantitative values, Hounseld
numbers, which are converted into electron density, relatively to water. This information is nec-
essary for planning algorithms to calculate dose with organ heterogeneity correction. The main
limitation of CT is that it cannot always identify the tumour adequately. Thus, other imaging
modalities are needed to give additional information. MRI provides better anatomical visualisa-
tion than CT, because of its excellent soft tissue contrast. However, it cannot be used directly
for radiotherapy planning due to geometric distortion and lack of electron density information.
PET and SPECT are functional imaging techniques, providing valuable and additional informa-
tion about patient and tumour physiology rather than anatomy. These imaging modalities use
nuclear tracers to assess the microscopic environment and to dene signicantly proliferative
areas within the tumour, tracking the distribution of a substance within the tumour cells. The
nuclear tracers used depend on what will be measured. However, these techniques have poor
spatial resolution and also do not provide electron density information, therefore they need to
be combined with and matched to CT imaging for radiotherapy planning [9, 22, 24].
Target Volume Denition
Delineation of target volumes (safety margins) should be performed during treatment planning,
in order to minimise the eect of geometrical uncertainties during treatment. The main volumes
to be considered in the treatment plan are reported by the International Commission on Radiation
Units and Measurements [33, 34], illustrated in Figure 2.7.
The gross tumour volume (GTV) is the gross demonstrable extent and location of the tumour;
the clinical target volume (CTV) includes the damaged tissue, which means GTV plus the area
directly surrounding it, which may contain subclinical malignant disease. This volume is the
main target to be eliminated in the treatment, in order to achieve the aim of the therapy, the
cure; and the planning target volume (PTV) is the CTV after geometric expansion, including
uncertainties in the planning and treatment process, in order to ensure that the prescribed dose
is actually absorbed in the CTV. It is also important to take into account other treatment plan
components, such as the organs at risk, which are the normal tissues that can suer radiation
damage during treatment; the planning organ-at-risk volume, which is analogous to the PTV, but
applies to normal tissues; and the remaining volume at risk, which consists of non-contoured
parts of the patient. All these components are important to create the treatment plan of the
patient.
The treatment is then planned so that the PTV receives the required tumour dose and the
dose limits are dened for the organs at risk. The beam geometry is also designed and the dose
distribution is calculated and evaluated [10, 23].
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Figure 2.7: Illustration of the volumes delineation as dened by ICRU 50 and 62 reports. Adapted from [12].
Dose Planning
The patient’s body is not homogeneous, which means each organ presents a dierent dose dis-
tribution and a dierent sensibility to the radiation. The dose planning step is used to obtain the
beam shapes and dose distributions correspondent to each structure previously delimitated. This
is done in order to maximise tumour control and minimise normal tissues complications [9, 12].
The treatment planning system generates the patient plan according to the best and most
adequate technique to the treatment and target volume delineation. It uses three-dimensional
(3D) imaging information of a patient to model the position and shape of both tumour and healthy
tissue. Therefore, an optimum beam conguration, including photon beam energies, eld sizes,
shielding beam directions and relative weighting, can be determined and heterogeneities can be
corrected, using specic calculation algorithms. Monte Carlo, which is the most accurate tool,
simules the interaction of millions of photons with matter, using basic physics interactions. It also
utilizes probability distribution signicantly close to reality [6, 35]. Other algorithms faster than
Monte Carlo model treatment beams use measurements of dierent beams. For every algorithm,
the quality of the dose representation is strongly dependent on the parameters used. At the end,
all beam parameters, which are needed to set up the linear accelerator, are dened and a 3D dose
distribution inside the patient is obtained. The TPS also allows to simulate the treatment, used
in quality assurance, in order to predict how it should occur, aecting the healthy tissue as little
as possible [6, 9, 35].
As described above, as far as IMRT is concerned, the treatment planning takes into account
the inverse planning, in which the clinician denes, at the beginning of planning, the tumour
and OARs, the beam conguration and the radiation dose that he wants to deliver to the target
tissue with an optimisation computer program. On the other hand, the 3D-CRT uses the forward
planning, in which dose distributions in the relevant target volumes and OARs are evaluated at
the end of the planning process, as also described above [36].
Once the plan is conceived, the patient-specic QA is performed to ensure its accuracy and
approval. After approval, the data is transferred to the treatment machine.
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State of the Art: Patient-specic QA of IMRT
The next and last step of pre-treatment is quality assurance. It is one of the three very important
requirements in a radiotherapy treatment, which are an accurate delivery system, a treatment
planning system and, nally, the QA process. The latter guarantees that the prescribed treat-
ment is accurate and according to the planned and clinically acceptable error tolerances. The
complexity of the dose delivery and the resulting distributions require the performance of mea-
surements, in order to verify the accuracy of the calculated dose distributions. Looking back
in time, the QA has been an integral part in clinical trials since 1972, while being part of the
Radiation Oncology Committee for the original Cancer and Leukemia Group B [37]. However,
when IMRT was proposed and implemented in many centres, a new clinical routine had to be
adopted due to some particularities of the IMRT: complexity, need of higher accuracy, great po-
tential for delivery errors and higher dose delivered [12]. The importance of carrying out a QA
process to the IMRT equipment and to the patient’s treatment planning has been discussed and
emphasised in many papers, reports and books (e.g. report of the Intensity Modulated Radia-
tion Therapy Collaborative Working Group (IMRTCWG) [38], Ezzell et al. [39], and others that
will be mentioned further) [40]. On the one hand, this change on radiotherapy resulted from the
emergence of new and better technology, devices, software and treatment techniques, modifying
and improving the way processes occur; on the other, a very important goal is continually kept:
reduced dose delivered to the patient.
There are two types of QA methods, machine QA and patient-specic QA. The rst one is
responsible for checking and assessing the machine characteristics and its performance, detect-
ing mechanical errors and verifying if some parameters are on the baseline values. The second
one, the patient-specic QA, should nd transmission errors and computational dosimetry er-
rors of the treatment planning. This type of QA assures the quality of each patient’s treatment,
ensuring a correct and accurate dose delivery to the patient and guaranteeing the treatment plan
does not deviate from what was planned previously [28, 41]. Patient-specic QA, illustrated in
Figure 2.8, can be performed by measuring the dose in a phantom using the patient plan, and
comparing what was measured with the dose calculated by TPS. Afterwards, the evaluation of
dose distributions is performed.
Figure 2.8: Illustration of the specic-patient QA of IMRT process. The process consists of the dose comparison
between the plan of the treatment calculated by TPS and the same plan of the treatment measured with a lm, diode
array, IC array, EPID, among other systems. Adapted from [42].
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The practice of IMRT QA is widespread, and there is no a standard and denite way to per-
form it, which means methods of IMRT QA vary from institution to institution [40, 43]. Never-
theless, there are several reports and papers which describe all this process in detail, reporting
some briengs, rules and parameters to take into account and giving information about several
devices used (e.g. Fraass et al. [44], report of the Intensity Modulated Radiation Therapy Collab-
orative Working Group [38], Ezzlle et al. [39], Low [45], Galvien et al. [46], Nelms et al. [43],
report of ESTRO Booklet No. 9 [40], Low et al. [46]). For instance, Nelms et al. [43] carried out
a survey about methods of IMRT QA in some institutions, even though only with users of an
electronic two-dimensional diode array device. ESTRO Booklet No. 9 [40] shows examples of
the way patient-specic IMRT QA is performed in many institutions where it is adopted.
Several ways of performing patient-specic IMRT QA have been suggested, for example,
using ion chamber, lms, diode arrays, electronic portal imaging device (EPID) and gel dosimetry
to measure dose distributions in a phantom [41, 47]. These devices and methods are used as
dosimeters and they have to be as accurate as possible in order to measure the dose distribution
that can be compared with the calculations. This way, it is possible to detect and mitigate errors
in TPS and in the delivery system, as previously said.
Ion chambers have been used from the beginning of IMRT dosimetry due to their excellent
stability, linear response to absorbed dose and small directional dependence. They are water-
proof and they have cylindrical symmetry. Ion chambers perform a point-dose measurement,
verifying absolute dose distribution in a certain dose point [47]. However, they do not allow to
obtain absolute dose distribution in all the plan that provides more information about it than just
analysing a point-dose of the evaluated plan. Taking this factor into account, 2D ion chamber
arrays were developed and they are less time-consuming, allowing fast analysis and immediate
readout of dose distributions. A drawback is the separation between the ion chambers on the
array, requiring interpolations of readings which limit the spatial resolution [28, 31].
MatriXX (Scanditronix Wellhofer, Germany) is an example of an ion chamber array based on
a pixel-segment ionisation chamber (PXC) designed by Amerio et al. [48] and tested by Stasi et
al. [49]. This array consists of 1020 cylindrical ion chambers, arranged in a 32 × 32 matrix, with
a volume of 0.08 cm3 and with a distance of 7.62 mm between chamber centres. It also has an
active area of 24.4× 24.4 cm2. This device is adequate for planar dose measurements of absolute
dose, and it is an device with both suciently high accuracy and speed for measurements in
radiotherapy [27, 50].
Seven29™ (PTW, Freiburg, Germany) is another example of a two dimensional detector array
described by Poppe et al. [51] and evaluated by Spezi et al. [52]. This device is the version 2 of
2D-ARRAY reported by Poppe et al. [51]. Version 1 has 256 (air-lled) ion chambers arranged in
a 16 × 16 matrix covering an area of × 27 cm2 and version 2 (Seven29™) has 729 (air-lled) ion
chambers arranged in a 27 × 27 matrix also covering an area of 27 × 27 cm2, both arrayed in a
square pattern. The ion chambers from Seven29™ are equally spaced 1 cm centre to centre and
each ion chamber has a size of 0.5 × 0.5× 0.5 cm3, surrounded by a material called polymethyl-
methacrylate (PMMA). This detector is easy to use for daily IMRT QA, measuring the absolute
dose. It reduces the workload when compared with conventional techniques and the dose distri-
butions are acquired, shown and potentially processed quickly. For these reasons Seven29TM is
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a dosimetrically accurate and sensitive tool for IMRT QA [47, 53]. However, it fails in the veri-
cation of gantry, collimator and couch angles and still do not correlate the measured composite
dose distribution to the patient’s anatomy [54].
Diode arrays are diodes arranged in a matrix (array) and they have also been one of the
devices used for patient-specic IMRT QA, because they are more sensitive than ion chambers,
they are easy to use and they provide QA results while measurements are being performed [55].
MapCHECK® (Sun Nuclear Corporation, Melbourne, FL) is one of the most popular commercially
available arrays. It was rst described as a prototype by Jursinic and Nelms [56] and evaluated
by Létorneou et al. [57, 27]. This device contains 445 n-type diodes distributed over an area of 22
× 22 cm2. The 10 × 10 cm2 central area contains 221 diodes with 7 mm spacing, and the outer
region surrounding the central grid contains 224 diodes with 14 mm spacing [27, 57]. This device
can measure the absolute and relative dose distributions on a phantom, simplifying and reducing
the IMRT QA workload, because it can eliminate some of the steps involved, for instance, in lm
dosimetry [55, 57].
Films are traditionally the device used since the beginning of IMRT dosimetry, evaluated for
this process by Bucciolini et al. [58] and Ju et al. [59, 50]. Unlike ion chamber, lm can be used
to measure relative dose distribution in a plan that will be used to verify the treatment plan in a
phantom [28]. There are two types of lm used in patient-specic IMRT QA: radiographic and
radiochromic lm. The rst one consists of a clear lm base coated in an emulsion containing
silver halide and it is not water-equivalent. There are several commercial radiographic lms
including Agfa, Fuji, Kodak, and Konica. Unlike radiographic lm, the radiochromic lm is nearly
tissue-equivalent and EBT-2 is the only lm commercially available with appropriate sensitivity
[47]. The selection of the right lm to use should be done based on the expected maximum dose
to measure. Both types of lms have high and good resolution. However, performing QA with
lm is a time-consuming process due to its calibration, scanning process, phantom setup and
lm analysis [60].
The two-dimensional detector arrays, as ion chamber and diodes arrays detectors, have grad-
ually replaced lm measurements due to their ease of use; simple setup; immediate achievement
of the results after dose delivery; less time consumption; and their potential for increased e-
ciency of the measure, on grounds of their capability to provide a large number of dose measure-
ments in a single irradiation per beam. They provide two-dimensional analysis of dose distribu-
tion. On the other hand, they can also provide three-dimensional analysis of dose distribution
using specic reconstruction software that allows to analyse the dose distribution taking into
account the three dimensions, obtaining more dose distribution information. However, they are
planar dosimeters, i.e. they contain few detectors and its geometry is not the best for gantry
rotation [47]. To overcome this drawback, there are the three-dimensional dosimeters, which
make a more complete acquisition of IMRT dose distribution, providing also 2D and 3D dose
distribution evaluation.
Delta4 (ScandiDos AB, Uppsala, Sweden) is an available example of three dimensional detec-
tors. More details about this system can be found in publications by Bedford et al. [61], Korreman
et al. [62] and Sadagopan et al. [54], where it is possible to nd descriptions and some assessments
of this system [41]. This device shows a bi-planar detector geometry, consisting of a cylindrically
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shaped PMMA phantom. It is composed by 1069 p-type cylindrical silicone diodes arranged in
a rectangular matrix along two orthogonal planes (cross-sectional). The diodes have a volume
of 0.04 mm3 and are spaced 0.5 cm centre to centre in the central area (6 × 6 cm2) and 1 cm in
the outer area (20 × 20 cm2) [61, 62, 63]. The detector planes are placed in an acrylic cylindrical
phantom with 22 cm of diameter and 40 cm of length [64]. Its orthogonal shape provides full
coverage of the cross section of any beam direction while dose measurements are done with the
gantry rotating. Nevertheless, the device does not take into account all dose delivery angles, due
to its cross shape [64]. IMRT QA, provided by Delta4, is a complex, laborious and time consum-
ing procedure [54, 61]. However, this detector has the necessary capacity of reproducibility and
it is suciently accurate and stable to perform ecient patient-specic IMRT QA [54].
ArcCHECK® (Sun Nuclear Corporation, Melbourne, FL) is a competitive device created to re-
solve the need of rotational IMRT QA, due to its cylindrical shape. It was presented by Létourneau
et al. [65] and Yan et al. [66] as a suited dosimeter for IMRT QA [67]. Thus, this detector is a
cylindrical acrylic (water-equivalent) phantom with 1386 diodes. They are arranged on a helical
grid to reduce the amount of detector overlap and to obtain more three dimensional view of the
measured dose distribution as compared to a 2D array measurement [68][69]. This detector is
suitable to accurately measure both relative and absolute doses and it allows measurements at
arbitrary gantry angles with sucient spatial resolution, although it still has low resolution [67].
It is also easy to set up and its performance is a less time consuming process.
The last two detectors described are also considered phantoms, which are constructed us-
ing either water or water-equivalent plastic, as acrylic. Water phantoms can be used when the
beam is perpendicular to the phantom surface, and where great exibility in detector positioning
is desired. In case of water-equivalent plastic phantoms, they can be used with multiple detec-
tors, as lms, ion chamber, and rapid and ecient setup [47]. An example of this phantom Is
OCTAVIUS® described by Van Esch et al.[70]. This octagonal polystyrene phantom is used with
the ion chamber, described above, Seven29™ [41]. Its octagonal shape is advantageous as it allows
easy positioning for measurements in multiple plans [70].
EPID is the promising device, which reliably and accurately measures absolute dose distri-
bution. It has also replaced the traditional dosimetry devices in the clinic for plan verication in
some institutes, because they have few measuring points and therefore a low spatial resolution.
van Elmpt et al. [71] made a detailed bibliographic review about the use of EPID in dosimetry
and its applications, about several types of EPID that appeared since the beginning and about
respective evaluated studies. EPID emerged, as a dosimetry device, in the late 1980s/early 1990s
at Netherlands Cancer Institute, Amsterdam by Meertens and van Herk [72, 73, 74]. This detec-
tor was described as liquid-lled ionisation chamber EPID (Li-Fi EPID or SPLIC EPID) [75] and
consisted of a matrix of 256 × 256 ionization chambers lled with an organic liquid (isooctane)
over an area of 32 × 32 cm2. It can convert measured dose-rate to absolute dose by recording
a continuous readout of the monitor chamber signal of the LINAC during image acquisition, as
well as by recording the number of monitor units delivered for the measurement dose image.
The scintillation crystal-photodiode detector ‘RTIM-AGE’ is the second and non-commercial de-
tector developed in the beginning of the 1990s at the Royal Marsden Hospital in London by
Morton et al. [76] and was used for dose measurements. The following detector, Camera-based
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EPID, consists of a uorescent phosphor-screen with a metal plate on the top that converts high-
energy photons into visible photons. The most common type of EPID available nowadays is the
amorphous-silicon EPID (a-Si EPID) or at-panel imager, described by Antonuk et al. [77, 78]
in 1995. The detector consists of an X-ray converter, light detector and an electronic acquisition
system for receiving and processing the resulting digital image. When the a-Si EPID emerged,
the interest in EPID dosimetry increased especially due to its favourable characteristics, such as
fast acquisition, ease in measurements at dierent angles, high resolution and contrast, digital
format and analysis tools and potential for in vivo measurements and 3D dose verication. It
also allows the measurements for any gantry angle, due to the fact that it is linked to the LINAC,
following the gantry in each positon [71].
Finally, Gel-dosimetry, still in the development stage, is the method which guarantees high
resolution, accuracy and precision. Two types of gels, polyacrylamide (PAG) and Fricke gels are
used together with methods of dose-readout techniques, as magnetic resonance (MR) imaging
and optical-computed-tomography (optical-CT). The rst one consists of bis, acrylamide, nitro-
gen, and gelatine. It uses the mechanism of radiation-induced polymerisation of monomers,
where small monomer molecules join together under the inuence of the dose. The second one
is rst described by Gore et al. [79]. This gel is easy to produce and reliable. However, it has
a drawback related with the fact that the radiation-induced ferric ions diuse through the gel
matrix, leading to the degradation and eventual loss of the recorded dose distribution [27, 45].
Gel-dosimetry allow to do 3D dose reconstruction, determining the dose distribution in all vol-
ume, obtaining a complete dose distribution information.
Several studies (e.g. Chandraraj et al. [80], Defoor et al. [64], Feygelman et al. [63], Fredh
et al. [41], Hussein et al. [81], Li et al. [52]) were developed in order to compare many of the
systems described above and test their capacity to accurately carry out specic-patient IMRT
QA. For instance Fredh et al. [41] compared four measuring systems (Delta4, OCTAVIUS, COM-
PASS (MatriXX) and EpiqaTM (Epid)) intentionally introducing errors in the clinical plans. The
systems are able to detect errors. Delta4 and Epiqa were more eective on the detection than
the other two systems. Finally Feygelman et al. [63] compared ArcCHECK with Delta4 and also
proved their ability to carried out QA IMRT.
After dose distribution acquisition via a detector and phantom, the dosimetric analysis must
be carried out, where the calculated dose distribution is compared to the measured dose distri-
bution. This analysis is done using one of these methods: dose dierence, distance-to-agreement
(DTA), gamma analysis and dose volume histogram.
The rst one is a straightforward and intuitive method and consists of calculation point by
point in dose domain of the absolute or relative dierence of two (calculated and measured) dose
distributions [82]. The second one was developed by Van Dyk et al. [83] and applied in a soft-
ware tool to compare two-dimensional dose distribution by Harms et al. [84]. DTA measures the
closest distance from a point in reference dose distribution to a point in evaluated dose distri-
bution [82, 85]. Gamma analysis is the most common method used for IMRT two-dimensional
dose distribution comparison, because it is very dicult to compare it via dose dierence in low
gradient region and via DTA in high gradient region. This happens due to the unsystematic pres-
ence of low and high gradient regions. Gamma analysis incorporates both dose dierence and
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DTA methods. It is, therefore, more sensitivity in these regions, faster and more accurate too,
and produces a quantitative test based on both dose and spatial criteria [86]. Low et al. [87, 88]
developed this method, which provides a numerical quality index, gamma value (γ), that serves
as a measure of disagreement in the regions that fail the acceptance criteria and indicates the
calculation quality in regions that pass.
Although gamma analysis is the most common tool used in dose distribution comparison,
several recent studies demonstrate problems with important clinical implications when perform-
ing patient-specic QA based on the gamma index method. Nelms, Zhen and Tomé [89, 90]
started to study the sensitivity and specicity of the gamma analysis. Their studies, as well
as others, reached the following conclusions: lack of correlation between patient dose errors
and gamma passing rates (%GP) for IMRT QA, which means, gamma analysis can hide the ex-
istence of errors in clinically relevant regions, taking into account points in clinically irrele-
vant regions [89]; lack of correlation between global gamma indices and clinical DVH metrics
[90, 91, 92]; gamma method inability to guarantee the absence of clinically signicant dose de-
viations [93, 94, 95]; and, nally, existence of poor accuracy, sensitivity and specicity of the
standard gamma algorithm [96, 97].
Dose-Volume Histogram is the promising method to overtake the lacks that result from the
use of gamma analysis, the former being a signicant and powerful tool in treatment approval
with three-dimensional dose distributions (3D). DVH was introduced by Drzymala et al. [98]
and consists of a 2D graph, which summarises data of 3D dose distribution per volume for the
patient’s specic organ, providing some statistical information as well. 3DVH® (Sun Nuclear
Corporation, Melbourne, FL) is an example of a pre-treatment software that creates DVH for
each organ of a patient plan. It uses data from MapCHECK and ArcCHECK QA measurements
to estimate the 3D dose delivered to a patient. Thus, it allows to compare delivered and planned
patient DVH and also mean, minimum and maximum dose of regions of interest (ROI), using a
computational algorithm named Planned Dose Perturbation (PDP™)[90, 99].
QA Measurements
• ArcCHECK
ArcCHECK (Sun Nuclear Corporation, Melbourne, FL) has been developed for routine IMRT
QA, specically for VMAT, due to its cylindrical shape. ArcCHECK is a cylindrical water-equivalent
phantom with a three-dimensional array of diode detectors, arranged in a helical geometry,
which provides consistent and highly sensitive measurements for all gantry angles, as visible
in Figure 2.9. It can make both relative and absolute dose measurements in an ecient and ac-
curate way. It also allows to obtain the two-dimensional dose distribution reconstruction as well
as the three-dimensional dose distribution reconstruction with auxiliary software. Its interface
is SNC Patient software, which is used to analyses the data measured on the QA. 3DVH is the
software used to perform the 3D dose distribution analysis [67].
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Figure 2.9: Representation of the dose distribution measurements using ArcCHECK for four gantry angles and its
diodes helical matrix. Adapted from [100].
• EPID Dosimetry
EPID is the most recent and ecient device to measure dose distribution used in patient
QA. It was originally designed for verication of patient position by analysing the portal image
obtained. However, another capacity was put into practice: the ability to obtain dosimetric in-
formation for pre-treatment verication and in vivo dosimetry, due to the fact that EPID images
contain dose information [71]. Thus, EPID converts portal dose image into dose distribution in
a patient/phantom via a back-projection algorithm. The image is obtained via the generation of
electrons by an incident MV photon beam, which means, pixel values in the EPID images are
related with absolute dose values in the phantom or patient [5, 47, 60]. Thereby, back-projection
algorithm, described by Wendling et al. [5], allows to compare the calculated dose distribution
with the delivered dose distribution in the patient or phantom, enabling the two-dimensional
dose reconstruction in the patient from portal images, and, as required, providing information
for three-dimensional dose reconstruction [5]. EPID is attached to the LINAC and follows all the
gantry rotation around the patient.
The amorphous silicon EPID is the device used mostly for EPID dosimetry. It consists of an
X-ray converter, the light detector and the matrix of amorphous silicon detectors to receive and
process the resulting digital image, as presented in Figure 2.10. The X-ray converter consists of
a metal plate of copper placed on top of a detector scintillating phosphor screen that is typically
made of terbium-doped gadolinium oxysulde (Gd2O2S : Tb) or Cesium-iodide (CsI). The rst
layer, which acts as a build-up, produces Compton electrons from incident photons and absorbs
scattered radiation that reduces the image contrast; and the second layer converts the photons
into optical photons (light). This is detected by a matrix of pixels, being each pixel composed of
photodiodes and thin lm transistors (TFT). The photodiode absorbs visible light and the TFT’s
act like a switch to control the readout of the signal. In the end an image frame is obtained
[101, 102]. In terms of dosimetric capabilities, the light signal measured at each pixel can be
related to the dose distribution inside the phantom, which means, each pixel value in the portal
image obtained by EPID measurements is related to dose values on the phantom. In other words,
the measured grayscale portal image is converted into a portal dose image. From this portal dose
image the energy uence - the total energy of the photons passing through an area that exit the
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LINAC - is extracted and the dose on the phantom/patient is calculated from here [4, 103].
Figure 2.10: Illustration of EPID constituents and X-ray conversion. Adapted from 101.
In EPID dosimetry there are some factors to take into account: verication procedure can be
classied according to whether or not they are performed during treatment, which means in vivo
(with the patient) or outside of treatment (without patient). Dosimetry methods can be grouped
according to whether or not beams have passed through an attenuation medium between the
source and the detector (non-transmission dosimetry) or if the dose is reconstructed inside a
phantom or a patient (transmission dosimetry) [71]. Also, it is important to take into account if
the measurements and calculations are done and compared at the EPID level (forward-projection)
or if the measurements data is projected into the patient/phantom, i.e. it is possible to reconstruct
the dose in the patient/phantom level (back-projection). The last one can be used for in vivo
dosimetry [5]. These factors are presented in Figure 2.11.
Figure 2.11: Two approaches of EPID Dosimetry, where in each it is possible to obtain the dose distribution at the
EPID level (forward-projection) or at the patient/phantom level (back-projection). Adapted from [71]
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Dose Distribution Evaluation Methods
After measurements it is necessary to decide if the plan is acceptable for the treatment, wherein
the dose measured and calculated distributions are compared using quantitative and ecient
methods. There are four important dose evaluation methods: Dose Dierence, Distance-to-
Agreement, Gamma Analysis and Dose-Volume Histogram [85].
• Dose Difference
As previously described, dose dierence is a method of dose distribution evaluation and it is
the most straightforward and intuitive method used. It consists in a point-by-point calculation of
the dierence between two dose distributions, the reference dose (Dr) and evaluated dose (De),
in dose domain. This method allows to know how much two dose distributions disagree [82, 85].
The dose dierence, ∆D, can be used to dene an acceptance criterion, determining if the
plan passes or fails. The most used common dose dierence criterion is ∆D =3% of the maximum
dose [88, 104]. This criterion can be used in low gradient regions, but it is inadequate in high
gradient regions, because a small alignment error in the last mentioned region can translate into
a big dose error, which means this method is not suited for this region [87, 105].
• Distance-to-Agreement
Distance-to-Agreement is another dose distribution evaluation tool that is based on the local
dose gradient. It is described by the spatial distance between a point in the reference distribution
and the closest point in the evaluated distribution that shows the same dose. DTA at a position
(~rr) is presented in the next equation 2.2:
DTA(~rr) = min{|~re − ~rr|}, ∀{~re}, where De(~re) = Dr(~rr), (2.1)
~rr is the reference position and ~re is the evaluation position [85, 104].
The distance-to-agreement criterion, ∆d, is the spatial tolerance and is also assumed as an
acceptance criterion, determining if each point passes or fails this dose distribution evaluation
test. The most common distance-do-agreement criterion is ∆d =3 mm. This criterion does not
work on low gradient region, but in high gradient region where it is more sensitive [85, 104, 105].
• Gamma Analysis
Gamma analysis is the most used dose method to compare two dose distributions, taking
into account both dose and spatial dierences between them. It provides a numerical quality
index, gamma value (γ), that works as a measure of disagreement in the regions that fail the
acceptance criteria and indicates the calculation quality in regions that pass. Thus, it represents
the minimum multidimensional distance between the reference and the evaluated points in a
space composed of both dose and physical distance coordinates. It is calculated based on the
normalised percent dose dierence (%Di) and distance to agreement (DTA). The analysis pro-
cedure starts by normalising doses and spatial coordinates. The two dose distributions to be
compared are assigned as reference (Dr(~rr)) and evaluated (De(~re)) dose distributions. For each
21
Chapter 2. Background
point in the reference distribution, the normalised distance to each point in the evaluated dis-
tribution is measured, where the distance includes both normalised spatial and dose values. γ
value is the closest approach (minimum distance) of the reference distribution, being unity when
the closest approach of the reference distribution is in the unit sphere. The unit sphere indicates
the region where the comparison test passes. Thus, if the reference distribution is inside the unit
sphere, the γ test passes, otherwise it fails [47, 105].
For the vector position of the evaluated (~re) and reference (~rr) points the γ is governed by
the following two equations:










where r(~re, ~rr) = |~re − ~rr|, is the spatial distance between the evaluated and the reference
positions, δ(~re, ~rr) = De(~re)−Dr(~rr), is the dose dierence between the two positions analysed,
∆D is the acceptance dose dierence criterion and ∆d is the acceptance DTA criterion.
When
• γ(~rr) ≤ 1, the test passes;
• γ(~rr) > 1, the test fails.
Figure 2.12 shows a schematic representation of the gamma analysis tool in 2D, denoted by
an ellipse.
Figure 2.12: Graphic explication of the gamma method. The dierence of reference data and the evaluated data are
presented in a dose as function of distance graph. The gamma value limits are presented, being possible to see the dose
(y axis) and distance dierence (x axis), observing if these are large or in the limits imposed (∆D, ∆d respectively),
which means, if the dierence between both data is within the ellipse, the test passes, and if it is outside of the ellipse,
the test fails. Adapted from [106].
There are three important parameters to take into account on gamma analysis: %Di, DTA
(already described) and dose threshold. This consists of the percentage value that rejects the dose
points below the dose threshold chosen of the planned maximum dose. Finding the best value
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for the three parameters is a somewhat complicated task: there has been no agreement as to the
best values for the criteria [55]. This can also be a drawback of the method that can aect the
analysis, in addition to the others previously described. However, some previous studies (report
of the AAPM Task Group 119 [107], Both et al. [55] and Basran and Woo [108]) assert that 3%
for %Di and 3 mm for DTA are the most common criteria at 10% for dose threshold value and
with an accepting threshold of gamma passing of 90% [55, 89].
• Dose-Volume Histogram
Dose-Volume Histogram is the promising tool to be implemented in quality assurance, being
already a powerful tool used on planning treatment. It quanties and summarises in a 2D graph
the data of 3D dose distribution per volume for the patient’s specic organ, providing some
statistical information as well. It is very useful for assessing tumour volume coverage and also
the dose delivered to healthy tissue surrounding the target, revealing the presence of hot spots in
it [98, 109]. There are two types of DVH (Figure 2.13): dierential (or direct) and cumulative (or
integral) DVHs [12, 19]. The DVH is created by portioning the volume of interest into volume
elements, called voxels, which are small enough in order to avoid dose variations on the voxel.
The rst type of DVH, dierential DVH, is a histogram and represents the sum of the number
of voxels with a particular dose, resulting in a plot of the absolute volume or the percentage of
the total organ volume as a function of dose. The second type of DVH, cumulative DVH, is more
popular than the other type and also shows the percentage or the absolute volume as a function
of dose of a specic organ. However, herein is represented the volumes of the targets that receive
at least the dose indicated in the dierential DVH. In case of percentage volume as a function
of dose, it starts at 100% of the volume for 0 Gy, since all the volume does not receive no dose
[12, 19].
Figure 2.13: Illustration of the two types of DVH and how they are constructed. The two selected voxels in Dose
Distribution (image on the left) are correspondent to a lower dose (the one on the edge) and a high dose (the one on
the centre). Afterwards, they are represented in the Dierential DVH (image in the centre) in a low and high dose bin
according to the dose received by each voxel. In the Cumulative DVH (image on the right), the total volume of the
structure that receives at least the given dose in the dose bin indicated in the dierential DVH is represented [19].
There are some important parameters that can be derived directly from DVH and that agree
with the recommendations from the ICRU Report 83 [110]:
• Dmin: the minimum absorbed dose by the target volume;
• Dmean: the mean absorbed dose by the target volume;
• Dmax: the maximum absorbed dose by the target volume;
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• D98%: the near-minimum dose, i.e. the minimum absorbed dose that covers 98% of the
volume;
• D50%: the median dose, i.e. the absorbed dose received by 50% of the volume;
• D2%: the near-maximum dose, i.e. the maximum absorbed dose in the target volume or
minimum absorbed dose that covers 2% of the volume;
• and other points specic of some organs.
2.3.3 Treatment Delivery
Prior to each treatment, it is necessary that the patient is set up in the same position as he was for
the planning scan to assure the radiation is delivered to the correct location. Several hardware
and software are used in the treatment. The most common involve a linear accelerator (LINAC)
with rotating gantry and moving MLCs.
As previously referred (subsection 2.1.2), the treatment is often performed in a fractioned
schedule, where the total dose is delivered with a small (1.8 to 2 Gy) dose per fraction ve times
a week. Typically, the treatment lasts from 5 to 8 weeks [12, 19].
2.3.4 Clinical Monitoring
During the treatment and after, the patients are submitted to monitoring consultations. It allows
the doctor to see the results of the treatment eects on the patient, in order to control the side




Taking into account all the limitations of the gamma analysis described in the last chapter (sub-
subsection 2.3.2, it is necessary to nd a better option to replace it. DVH seems to be the best
option for the IMRT QA, instead of gamma analysis.
This study intends to show the accuracy and relevant information provided by the DVH
analysis in the IMRT QA, testing a commercial software, 3DVH, intended to replace the gamma
analysis used in dose evaluation, which is the method carried out in Champalimaud Foundation.
The capacity of EPID dosimetry to calculate DVHs was also tested.
This chapter presents the main procedures and tools used in order to full the goal of the
study.
3.1 Overview of Dose Distributions Measurements and Analysis
This study, described in Figure 3.1, was performed using square elds plans and patient plans.
The patient plans, planned previously in Monaco® (v.5.00.04, Elekta AB, Stockholm, Sweden),
were irradiated with IMRT and VMAT using 6 MV and 10 MV photon beam and the square elds
plans were irradiated with 6MV photon beams. All was measured using the linear accelerator
of Elekta Synergy® LINAC (Elekta AB, Stockholm, Sweden) with 80 leaf MLC. The measure-
ments were performed with the iViewGT™ EPID (Elekta AB, Stockholm, Sweden), attached to
the LINAC, and ArcCHECK® (Model 1220, Sun Nuclear, Melbourne, FL), which is the device ac-
tually used for patient QA in Champalimaud Foundation. The dose distribution analysis was
performed using 3DVH® (v.3.3, SunNuclear, Melbourne, FL), of ArcCHECK, and an in-house de-
veloped program, pdDVH, of EPID. They provide a 3D reconstruction of the dose distribution
of the patient, calculating DVHs of each organ. The gamma analysis was performed by using
the software specic for EPID and ArcCHECK, pdapp (v.R1.0 C003, NKI-AVL, Amsterdam, ND)
and SNC Patient software (v.6.2.3, SunNuclear, Melbourne, FL) respectively. MLC and MU errors
were introduced in the square eld and patient plans to test the performance and accuracy of the
systems, using an in-house developed program.
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Figure 3.1: Schematic of the study workow.
3.2 Square Fields tests
The tests using square elds were performed to evaluate if the dose distribution given by the pro-
grams is correct and also to better understand the errors interference when they are introduced
in the plans. These tests were performed using a slab phantom of twenty slabs placed one over
the other. This phantom is the SP34 model of slab phantom from Iba Dosimetry® (Schwarzen-
buck, Germany). In this case, it consists of a set of twenty 10 mm thick and 30 × 30 × 30 cm3
square-shaped slabs. The material composition is water equivalent with approximately 98% of
white polystyrene, type RW3 and 2% of titanium oxide (TiO2), and its density is 1.045 cm3.
Three plans of a slab phantom were planned in Monaco, the treatment planning system as-
sociated to Elekta that uses the Monte Carlo and the Collapsed Cone algorithms to accurately
perform the treatment planning. Each one contains three structures: a PTV, a cube and a cylin-
der. The PTV, a 10 × 10 × 10 cm3 cube, intercepts the 6 × 6 × 6 cm3 cube at point 1.5 cm
of the latter. The PTV also intercepts the cylinder at point 1.5 cm of the latter. The cylinder
presents a diameter and a height of 6 cm. Three plans were created: the rst one (Figure 3.2
(a)) shows only one eld that will be irradiated with the gantry at 0°, the anterior-posterior (AP)
eld; the second one (Figure 3.2 (b)) shows two elds at 0°, the anterior-posterior (AP) eld, and
180°, the posterior-anterior (PA) eld; and the last one (Figure 3.2 (c)) presents four elds at 0°,
the anteroposterior eld, 180°, the posterior-anterior (PA) eld, 270°, the lateral right (LR) eld,
and 90°, the lateral left (LL) eld. All the elds were created in order to encompass the PTV and
they are conformal elds, which means, there is no dose modulation during treatment delivery.
The structures and elds sizes were generated automatically by the Monaco, because it uses the
inverse planning, described in the last chapter (subsection 2.2.2). Each plan was irradiated with
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6 MV photon beam from Synergy LINAC and was delivered on the slab phantom. All the plan
parameters are shown in Table 3.1.
Figure 3.2: Representation of the plans with specic elds and structures created in the slab phantom at the transverse
plan by the Monaco. On the left, (a) shows the rst plan with just one eld and the three structures created. The green
one is the cube, the red one is the PTV and the blue one is the cylinder. On the right, (b) shows the second plan with
two elds and also the three structures created and described previously. And on the centred, (c) shows the third plan
with four elds and the three structures created.
Table 3.1: Characteristics of the three plans created for the patient ZZZ1 of a slab phantom.
Patients Plan Energy (MV) Fields Fraction Dose (Gy) Monitor Units
ZZZ1 (AP) Slab Phantom 6 1 3.44 412.8
ZZZ1 (APPA) Slab Phantom 6 2 3.96 462.3
ZZZ1 (BOX) Slab Phantom 6 4 5.1 656.7
For the planning, a CT of the slab phantom was necessary and previously acquired by the
Philips CT system, Brilliance CT Big Bore (meter a Philips). The twenty slabs were placed on the
table, one on top of the other, forming the phantom structure to be acquired, as shown in Figure
3.3.
Figure 3.3: Illustration of the CT acquisition of the slab phantom in the CT room.
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The measurements with square elds were done with the leaf position and monitor unit er-
rors as a perturbation in the plans. The measurements were performed with both ArcCHECK
and EPID. For ArcCHECK measurements, the slab phantom was not used. For the EPID mea-
surements, the slab phantom simulated the patient and was placed on the table, again twenty
slabs one on top of the other, as shown in Figure 3.4.
Figure 3.4: Illustration of the setup of the measurements in the slab phantom in the LINAC room (a) and the slab
phantom (b).
The slab phantom was placed at the table so that isocentre was in the centre of the phantom.
This gave the SSD (Source-Surface Distance) distances, each associated to an angle, as presented
in Table 3.2. Each of these distances corresponds to the distance from the source of the treatment
machine, the LINAC, to the surface of the phantom.
Table 3.2: SSD parameters applied in the measurements.
Plan Angle (°) SSD (cm)
1 eld 0 90
2 elds 0 90
2 elds 180 90
4 elds 0 90
4 elds 90 83.5
4 elds 180 90
4 elds 270 86.7
The evaluation programs mentioned above were used to analyse the data, i.e. 3DVH, SNC
Patient, PreDose, pdapp and pdDVH.
3.3 Patient Plans Specication
Six cancer patient plans (one prostate and ve breast) were used in this study. They were previ-
ously planned and optimised using the Monaco treatment planning system and irradiated with
IMRT and VMAT dose delivery techniques, using 6 MV and 10 MV photon beam. A list of pa-
tients and its respective parameters is shown in Table 3.3. These were the patient samples used
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to test the accuracy of the systems used patient-specic QA and the interference of the errors in
complex plans. PreDose, SNC Patient and 3DVH were the evaluation programs uses to perform
the dose evaluation.
Table 3.3: Characteristics of the six patient plans used in this study.
Patients Type Plan Energy (MV) Fields Arcs #Fractions Dose (Gy) MU
ZZZ28210 IMRT BreastL 6 7 _____ 15 3.2 576
ZZZ8363 VMAT BreastR 6 _____ 2 15 2.7 985
ZZZ1295 VMAT Prostate 10 _____ 1 28 2.5 608.8
ZZZ34486 IMRT BreastR 6 7 _____ 15 3.2 618
ZZZ29113 IMRT BreastL 6 7 _____ 15 3.2 320
ZZZ11603 VMAT BreastR 6 _____ 2 15 3.2 919
3.4 Treatment Planning Files
As described above, all the plans were carried out with Monaco. During their planning the neces-
sary les, which contains the information required for the treatment delivery and also for the QA
measurements and evaluation, were generated. These les are in a DICOM format (Digital Imag-
ing and Communications in Medicine). DICOM is a way of standardisation for communication
of all systems and information necessary to the radiotherapy treatment. In other words, DICOM
includes a le format denition and network communication protocol, allowing the transmission
between any two entities that are capable of receiving image and patient data in DICOM format
[111].
There are four important DICOM les used during this study:
• RT Image, which consists of the relevant images to radiotherapy acquired by CT;
• RT Structure Set, which contains information related to patient anatomy, such as struc-
tures, regions, points and volumes of interest for the treatment;
• RT Plan, which contains geometric and dosimetric data of the treatment, such as informa-
tion about beam angles, collimator, couch and gantry angles;
• RT Dose, which contains dose data generated by the treatment planning system, Monaco.
3.5 Error Introduction
Multi leaf collimator and monitor units errors were introduced in the square elds and patient
plans, in order to test the accuracy of the systems on the detection of the errors and how it is
shown in gamma analysis and DVHs.
The errors were introduced in the patient plans using an in-house program, Modify RTP.
This software uses the RTP le of each plan, where the errors are introduced. The RTP les from
each original treatment plans were converted from RT plan DICOM le that was exported from
the Monaco treatment planning system. After errors introduction, the les were imported to
Monaco and converted into RT Plan les. RTP les contain all needed information for the Elekta
LINAC, in order to deliver the treatment eciently. It includes both basic patient information
and treatment information, such as the patient’s name and ID number, and the treatment name,
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the control points (CP), gantry angles, leaves positions per CP and the number of monitor units,
respectively. It organises the treatment information for each eld of the plan. Control points
dene the MLC shapes at a fraction of the delivered monitor units.
3.5.1 Multi Leaf Collimator Errors
Systematic and random leaf position errors were introduced in the patient plans using an in-
house program, modifying the RTP les, as described previously. When introducing systematic
errors, the position of each leaf was changed systematically, which means the position of all
leaves changes at the same value, ±3, ±2, ±1 and ±0.5 mm. The leaves position also changes in
a symmetric way, which means the leaves move in opposite directions, either closing or open-
ing. The negative errors correspond to leaves closing. The positive errors correspond to leaves
opening. These eects are illustrated in Figure 3.5.
Figure 3.5: Illustration of the eect of the MLC errors on the leaf position of an original plan. Systematic errors,
where negative errors cause the closing of the leaves and positive errors the opening of the leaves, and also random
errors. Adapted from [112].
The introduction of random errors, with standard deviation varying from 1 to 5 mm, changed
the position of each leaf randomly, as its name implies (Figure 3.5).
It is important to pay attention to the minimal leaf separation of the leaves when they are
closed in negative systematic errors introduction. This value is dened as 0.6 cm. The program
used shows for each eld all the control points and for each control point a picture with the
changes caused by the error in the leaves position. Figure 3.6 presents the interface used to




Figure 3.6: Illustration of the error introduction interface. It is an example of the change in the leaves position
caused by systematic error of -3 mm, which means the leaves close 3 mm. The new leaf position is represented by
the coloured leaves. In the interface it is possible to choose the patient, select the type of error to be introduced (in
this case, MLC errors and MU errors are highlighted), see the control points and the plan information, and save the
data. The example illustrated is from the error introduction process of a patient test.
A total of 14 modied RTP les were generated for each patient and for each square elds
test: the original plan without MLC errors, eight plans with the dierent systematic errors (±3,
±2, ±1 and ±0.5 mm), and ve plans with the dierent random errors (1, 2, 3, 4, 5 mm). They
were imported, for future dose distributions measurements, into MOSAIQ® (v.2.41.01J0, Elekta
AB, Stockholm, Sweden), which is the Elekta treatment management software. It contains all the
information regarding the radiation oncology program, that is, all patient treatment information,
and it is also used for the measurements.
3.5.2 Monitor Unit Errors
Monitor Unit errors were also introduced into the patient plans. MUs are used to measure the
output of the machine (LINAC) to deliver accurate dose. By convention, one monitor unit equals
1cGy of absorbed dose in water under specic calibration conditions for the LINAC [113]. MU
is a measurement of ionisation occurring in a treatment beam within the treatment head. The
errors change the total MUs value dened to each plan with magnitudes of -4%, -2%, 2% and 4%.
Systematic errors were the type of error chosen and consist in a constant percentage change in
the MUs for each control point within the plan. The same in-house program, Modify RTP, was
used. The interface is presented in Figure 3.6. In the end, a total of 5 modied RTP les were
created for each patient and for each square elds test: another original plan le without errors





ArcCHECK is the device used daily on Champalimaud Foundation to perform the measurements
of the patient-specic QA. After testing some devices, ArcCHECK was the chosen one, because
its phantom geometry and its capability to detect the presence of errors are better than those of
other devices and because it is easy to work with and set up.
3.6.1 ArcCHECK description
It consists of a 16 kg cylindrical acrylic phantom, which contains an array (21 cm in diameter and
length) of 1386 diodes detectors (SunPoint®) with size of 0.8× 0.8 mm2 and arranged in a helical
geometry (HeliGrid™) with 1 cm inter-detector spacing. The phantom has a length of 32.28 cm
and it has an outer diameter of 26.59 cm and an inner cavity diameter of 15 cm, as shown in
Figure 3.7. This cavity centre accommodates a PMMA plug, the CavityPlug™, with 1.183 g/cm3
of density, in order to eliminate the central cavity inhomogeneity. ArcCHECK also contains two
inclinometers, one to measure the angle of rotation of the cylinder and one for angle of coronal
angle (tilt); and a temperature sensor to measure the ambient temperature of the detector area
[68, 114].
Figure 3.7: Illustration of the ArcCHECK device and its constituent divisions. Adapted from [115].
3.6.2 Calibration and Measurements
The measurements with ArcCHECK were done for both square elds plans and patient plans.
This system is easy to set up, which is very important in QA process, in order to save as much
time as possible.
There are some procedures to full, when setting this device to the acquisitions. First of
all, the ArcCHECK is placed on the table over a support, in the LINAC room. Afterwards, it is
necessary to align the axis of the ArcCHECK, in order to position the device correctly. To do this
it is necessary to resort to the laser to align the transverse axis, moving the device and the table
until laser and device axis align. The coronal axis is aligned with the axis of a light eld which is
opened. The CavityPlug™ is placed inside the cavity centre and after this the device is connected
to the exterior data interface through a cable. The data interface is supplied by a power. Outside
the room, the device is connected to the computer that will acquire and save the data, using an
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USB cable. Figure 3.8 presents the ArcCHECK cabling and Figure 3.9 presents the device setup
in the LINAC room.
Figure 3.8: Illustration of the AcrCHECK setup. Device cabling and connection between interior and exterior of the
LINAC room. (a) corresponds to the ArcCHECK phantom, (b) is the ArcCHECK support, (c) is the cable that connects
the device to the exterior, (d) corresponds to the power supply, (e) is the line power cord, (f) is the USB cable that
connects the device to the computer and nally (g) corresponds to power/data interface. Adapted from [115].
Every day, before any QA, ArcCHECK calibration is done for the energies 6 MV or/and 10
MV, depending on which is needed for the measurement. This process consists in calibrating
the device for absolute dose using the SNC Patient software and allows for the correction of the
ArcCHECK measurements for the output variations of the LINAC.
The LINAC system is in service mode, instead of treatment mode, and a 200 MU beam with
a 10 × 10 cm eld is dened, which will be delivered to the device at a gantry angle of 0°. In the
SNC software the calibration option is selected, in order to do a measurement for each energy. In
the end, the known dose value specic to each energy, 249.7 cGY to 6 MV and 261 cGy to 10 MV,
is inserted in the SNC software. These values are obtained with the Monaco, creating an 10x10
cm2 open eld with 200 MU. Thus, the dose in the detectors is obtained theoretical.
Figure 3.9: Illustration of the ArcCHECK setup in the LINAC room.
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The measurements consist of simply selecting the patient and square eld plans in the MO-
SAIQ and, with the LINAC on treatment mode, clicking the button ‘beam-on’, in order to deliver
the dose to the device with gantry rotation. In the ArcCHECK software, it is just necessary to
click the button ‘start’, so that the SNC acquires the dose data, and click the button ‘stop’ at the
end of the measurement to save the data. The dose measurements from each sensor are updated
every 50 ms, saving all measurement data as a function of time of absolute dose measurements.
Each ArcCHECK measurement consists of the sum of all elds of the plan, which means, it is
not done eld by eld. The data is saved in three le extensions, *.txt that integrates correction
factors into the measurement and has the information about total dose in each detector; *.acm,
which consists of a multi-frame (movie) le that contains data from each diode for each update;
and *.acml, which is also a movie le and a binary format that contains calculated gantry angles
and dose information as a function of time for each measurement. The last one is the required
le for 3DVH software.
3.6.3 Dose Evaluation
After dose acquisition data, the dose evaluation was performed using the SNC Patient software.
This software allows to do a two-dimensional dose analysis from ArcCHECK acquisitions for all
gantry angles, as seen in Figure 3.10.
Figure 3.10: Illustration of dose distribution acquisition with ArcCHECK and the correspondent dose map obtained
on the SNC Patient software. Adapted from [116].
ArcCHECK displays the unfolded 2D proles from the cylindrical surface (Figure 3.10), being
possible to see dose distribution throughout the entire arc delivery. It was possible to make
an absolute dose comparison between the planned dose distribution calculated in the TPS and
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the measured dose distribution acquired by the ArcCHECK using gamma analysis, described in
the last chapter, at the acceptance criterion 3%/3 mm, which corresponds to 3% dose dierence
criterion and 3 mm distance-to-agreement criterion and with a threshold of 10%. The gamma
analysis was carried out taking into account the number of the diodes which satised specic
tolerances of dose dierences between calculations and measurements relative to the maximum
value on the calculated dose map (%Di) and DTA criterion. Only the diodes with the dose values
larger than 10% of the maximum value on the dose map were included in the analysis, because
it was the threshold chosen, as presented above; 3% dose dierence as a criterion used means
that only the values that show 3% or lower of dose dierence are taken into account; and 3 mm
distance-to-agreement criterion means that the values corresponding to the space between the
reference and the measured points with the same dose values are considered if it is 3 mm or
lower. These gamma analysis requirements are illustrated in Figure 2.12. The patient plan was
considered acceptable if the gamma passing rate was≥ 90%. This method just gives information
about dose distribution along the plan, only showing the points/detectors that fail and pass and
also 2D gamma passing rate value, but nothing about the dose distribution along each organ
volume and dose constraints. The points in the plan that fail are highlighted in red for high dose
and in blue for low dose.
This evaluation was performed comparing the measured data, which appears on the left-hand
side of the analysis window, as shown in Figure 3.11, with the planned data on the right-hand side
of the analysis window. The measured data is the ArcCHECK acquisition and the planned data
corresponds to the QA plan calculated in Monaco for the ArcCHECK measurements. It consists in
a plan with the same volumes created in the patient plan, but in this case, they were generated in a
structure. which was virtually created with the density and length of the ArcCHECK. SunNuclear
advised not to use the CT of the device, due to existence of image artefacts caused by the diodes.
Figure 3.11: Illustration of the ArcCHECK interface. It is possible to see the measured data (left side), the planned
data (right side) and the result, compared data, which is the gamma dose map. It is also possible to obtain the dose
prole for X and Y axis and dose statistic (above). The highlighted buttons on the left are selected for the gamma





The EPID used in this study is a at panel from Elekta, designed as iViewGT™ and based on
the amorphous silicon detector type of XRD1640 (PerkinElmer Optoelectronics, Fremont, CA,
USA) that is coupled to the LINAC gantry. This panel has a detection area of 41 × 41 cm2 that
consists of 1024× 1024 detector elements, pixels, with a sampling aperture (pixel size) of 0.4× 0.4
mm2. Its active area is composed of 1 mm thick copper plate and 0.54 mm thick terbium-doped
gadolinium oxysulphide (Gd2O2S : Tb) screen, which is xed at 160 cm from the target of the
LINAC. The entire panel elements are enclosed in a cover made of high-density polystyrene and
acrylonitrile butadiene styrene, presenting a thickness of 10 cm [101].
Figure 3.12 illustrates the general iViewGT™ a-Si EPID constitution described above, the its
external and internal components and the iViewGTTM a-Si EPID coupled to the LINAC in the
treatment room.
Figure 3.12: Illustration of the iViewGT™ a-Si EPID external (i) and internal elements (ii) and the same coupled
to the LINAC in the treatment room (iii). (a) corresponds to the copper metal plate, which, with the scintillating
phosphor screen (b), acts as an x-ray converter to optical photons detected by the active matrix array in order to be
converted in image (c), where each pixel is composed of a-Si photodiode (d) and TFTs (e). (f) is the data line, which
controls the readout of the charge of each TFT’s along a column, and (g) the gate control line that allows the signal
conduction of TFT’s along a row; (h) corresponds to the preampliers, which joined to the control gantry circuitry
(j) are the external electronics that amplify, process and digitize the imaging signal. Each data line is connected to a
preamplier. Adapted from [101].
3.7.2 Measurements
The measurements with EPID were performed both for the square elds plans and for the patient
plans. They allowed to obtain the necessary data to the dose evaluation software: PreDose,
pdapp and pdDVH. The rst two software allow to do a two-dimensional dose analysis from
EPID acquisition through gamma analysis, and the last one allows to do a three-dimensional
dose analysis from EPID acquisition through DVH analysis.
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The EPID is very easy to set up (Figure 3.13). One simply needs to open the panel, which
is already mounted in the LINAC gantry. The detector is connected to the computer with the
iViewGT (v.R3.4, Elekta AB, Stockholm, Sweden) acquisition software that provides the syn-
chronization between the EPID and the LINAC.
Figure 3.13: Illustration of the iViewGT™ a-Si EPID setup in the LINAC room.
For the measurements, it was necessary to have the LINAC on treatment mode and to select
the plan to measure on the MOSAIQ. The iViewGT had also to be open, in order to acquire and
save the data. The data was acquired eld by eld. For square elds and VMAT patient plans,
the measurements were made with rotation of the gantry. However, in IMRT plans and in case
of open images acquisition, an override of the gantry on 0° was done, because, as there is no
attenuation medium and the EPID follows the beam source during all the treatment, the gantry
can be on the same angle during the measurement.
Two types of measurements were done with EPID: the rst one without any attenuation
medium (patient/phantom) to obtain the so called open images, which are used in PreDose and
also in pdapp for both the square elds and the patient tests; and the second one with the slab
phantom, which is used in pdapp for the square elds test. Both software are described after.
The iViewGT software projects an image with a limited size. It scales the pixel and the
eld dimensions to 0.25 × 0.25 mm2 and 25.6 × 25.6 cm2 respectively, avoiding the acquisition
and computing of patients with big elds, because points outside of 25.6 cm square cannot be
accurately computed, due to the uence measurement to be not done for those points. The
obtained image is a sum of frames for each segment of the eld during the beam delivery. The
integrated pixel value (IPV) for each segment is obtaining using the following equation:




where the number 65535 is the 16-bit oset and PSF is the pixel scaling factor, which is reported
by the software for each segment. PSF, when divided into the pixel values of a corresponding
image, produces the dose result for the beam delivered. The acquired data is saved on a database
[117, 118].
A succinct explanation of the image acquisition was done above. These captured images
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contain dose information and for the QA process it is necessary to obtain these values of the
dose distribution in the main structures. These values are acquired by converting the image in
dose information. The grayscale image is then converted into a portal dose image, by assessing
the intensity of the EPID image pixels. The portal dose image has uence distribution data that
is used as input of a dose algorithm, for instance back-projection algorithm, to reconstruct a dose
distribution for the patient.
3.7.3 Dose Evaluation
The dose distribution in the data acquired by the EPID was evaluated by three software: pdapp
PreDose and pdDVH.
pdapp
pdapp is a software developed by the Netherlands Cancer Institute-Antoni van Leeuwenhoek
Hospital in Amsterdam and used in Champalimaud Foundation for research. This software is
mainly used for in vivo measurements with the patient. It always requires an attenuation medium
for the dose calculation. This software allows to perform the specic-patient QA comparing
the planned data with the measurements data performed with the phantom/patient. For this
comparison open images, the images previously acquired without any attenuation medium, are
also taken into account. It provides three types of analysis: beam 2D analysis, beam 3D analysis
and fraction. The rst one consists in analysing the 2D dose distribution eld by eld in a plane
through isocentre; the second one the 3D dose distribution eld by eld as well; and the last one
consists in analysing the 3D dose distribution per fraction (sum of all 3D beams). The latter is
the most frequently performed and necessary for pdDVH. The former two are more used in case
of doubt, because it allows to see what is happening in each eld. A summary of gamma analysis
is shown, containing the gamma passing rate value, the gamma means and the dose dierence
between the reference dose distribution and the measured dose distribution.
Figure 3.14 shows the interface of this software, where it is possible to see, on the left-hand
side, the measurement data, eld by eld. The rst data fraction, which stands out from the oth-
ers, corresponds to the open imagens and the other corresponds to the phantom/patient measure-
ments. It is also possible to observe the 3D planned and measured dose distribution, respectively,
in a CT of the phantom/patient. Under the images, the dierence dose map is observed, related
to the gamma analysis. If the gamma value presents a lower value (< -1), the point shows a blue
colour and corresponds to an underdose. On the other hand, if the gamma value presents a higher
value (> 1), the point shows a red colour, corresponding to an overdose. On the right-hand side
it is possible to observe the gamma analysis summary (described above) eld by eld or the total
evaluation, depending on what is intended.
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Figure 3.14: Illustration of the pdapp interface used to analyse the planned and measured data acquired by the EPID.
The example illustrated is from a 2 eld analysis of squared eld test.
The comparison between the planned and measured dose distribution in a phantom or patient
is done using the back-projection algorithm. It allows to reconstruct the dose distribution in
the patient/phantom, projecting in them the measurements done by EPID and the information
obtained from portal image acquired (Figure 2.11). There are some factors to take into account,
such as the dose-response of the EPID, the lateral scatter within the EPID, the scatter from the
phantom or patient to the EPID, the attenuation of the beam by the phantom or patient, the
distance from the radiation source to the EPID plane and to the dose-reconstruction plane, and
nally, the scatter within the phantom or patient. The detailed description of the algorithm was
done by Wendling et al. [5]. However, it is important to retain some equations that illustrate the
factors described above.
It is necessary to correlate the EPID pixel values with the dose values. As a reference data,
to t some parameters, ionization chamber measurements are used. They were performed with
the IC placed in the centre of a phantom with 20 cm of thickness, in order to measure the dose
in the isocentre. This is done for the reference eld size 10 × 10 cm2. The EPID images were
acquired and the intensity of the EPID image pixels provided dose information.
The dose DEPIDij at a certain pixel ij of the EPID consists in the sum of the portal dose
PDEPIDij of the radiation reaching the EPID directly with the scatter ScEPIDij within the EPID,






Firstly, it is important to relate dose values with pixel values, i.e. to determine the dose-
response function fDR of the EPID,
PV EPIDij = fDR(D
EPID
ij ), (3.3)
where PV EPIDij is the time integrated pixel value at a certain pixel ij of the EPID. It is assumed
that fDR is equal for all pixels of the EPID.




Another important factor is the existing scatter from the patient to EPID. In this case the
portal dose image PDEPID behind a patient includes this component, Scpatient→EPIDij , being






where PrEPIDij is the primary portal dose that results from radiation coming directly from the
head of the LINAC. In order to estimate the scatter contributions, it is necessary to calculate the
total transmission T total. The latter is obtained dividing the portal dose image with a patient
in the beam path by the portal dose image without a patient in the beam path (open image), as





The scatter contribution is then obtained by replacing the Equation 3.4 in Equation 3.5, ap-
pearing a new component, T primaryij that consists in the primary transmission, that is, the trans-
mission when no scatter from the patient can reach the EPID, as observed in Equation 3.6.
T totalij =








It is important to refer that the T total depends on eld size, but T primary has to be eld size
independent by denition. This allows to estimate the scatter contributions. T totalij is experimen-
tally obtained as a function of eld size, fs, by irradiating a phantom of a reference thikness, 20






Another required parameter is the total dose Dmid in the patient. Dmid consists in the sum







To calculate the primary dose, the Inverse Square Law (ISQL) and an attenuation correction
(AC) are used, joined to the primary dose of the EPID, as seen on the Equation 3.9,
Prmidij = Pr
EPID






where dreconst is the distance of the reconstruction surface from the accelerator target; dEPID
is the distance of the EPID from the accelerator target, which is 160 cm; and AC is related with
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the T primary , which is calculated by the following expression,
T primaryij = exp(µAC × tij). (3.10)
For dose reconstruction, the attenuation has to been corrected to the radiological path length
along a ray through the patient.
In the end, a three dimensional dose distribution can be obtained for simple elds, by recon-
structing the dose in dierent planes from the target, that is, by changing the dreconst for each
gantry angle. This dose can be compared direcly with the planned patient/phantom dose.
PreDose
PreDose is an in-house software, still under development, that allows to perform specic-patient
QA comparing the planned data with measured data, too. It is based on forward-projection,
because the comparison between planned and measured data is done at the EPID level. However,
instead of using the measured data with a phantom or patient and the open images, only the latter
are used. The open images measurements required for the software are illustrated in (Figure 2.11).
In this case, instead of measuring the dose at the patient level, by the back-projection way, it is
measured at the EPID level (PDEPID). This 2D dose image is estimated in the rst steps of the
previously mentioned back-projection algorithm (subsubsection 3.7.3), in which the expression
for EPID level calculation is described, more specically in Equation 3.2.
Using the Monaco treatment planning system, a QA plan is calculated using a 2 cm slab
phantom, simulating the copper plate of the EPID, overriding the slab phantom density by the
copper plate density, which is 7 g/cm3.
Figure 3.15 illustrates the interface of this software where it is possible to see some EPID
images and the dose distribution in the planned and the measured dose map, the gamma dose
map, the dose proles, all the settings and the box with the analysis data output.
Figure 3.15: Illustration of the PreDose interface.
The gamma analysis was also performed to all square elds and patient plans with PreDose,
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in order to be compared with the other systems. Hence, it was carried out to 3%/3 mm criterion,
3% of dose threshold for MLC errors analysis and 10% of dose threshold for MU errors analysis,
with 90% as acceptable criterion.
pdDVH
pdDVH (v.1.3) is another in-house software that calculates DVHs using dose data from pdapp
or DICOM RT dose. To obtain the DVHs, the following is necessary: reading the DICOM RT
Structure le of the calculated plan, the DICOM RT Dose le or the pdapp dose le and selecting
for which structure the DVH will be performed. The 3D pdapp was generated when the frac-
tion analysis is performed. Having these les, the software associates the dose values obtained
to the respective structure and calculates the DHV. With the DVH, it is possible to calculate
the measured dose distribution and to compare it to the reference dose distribution along each
constituent structure. It is also possible to calculate the respective dose statistics.
Figure 3.16 shows its interface where it is possible to see the dose distribution along the plan
in analysis, the structures constituents of the plan and its respective DVH. Also it is possible to
obtain and see the dose statistics of each structure.
Figure 3.16: Illustration of the pdDVH interface, where it is possible to see all its analysis options. The example
illustrated is from a 4 eld analysis of the cylinder in square eld test.
These analyses were just done to square elds test. The pdDVH uses the dose data from
pdapp. In the case of the square elds, the measurements with the slab phantom were carried
out with EPID in order to be used in pdapp, joined to planned data with slab phantom CT. In case
of patient plans, the in vivo measurements with errors were not possible to be acquired.
3.8 3DVH Analysis
3DVH allows to obtain DVHs of the main structures that are important to the treatment and that
should be analysed during the QA process. DVH would be a better dose evaluation method, still
to be implemented clinically to improve the patient-specic QA of IMRT. It can replace gamma
analysis, the conventional metric that is limited in sensitivity and specicity. 3DVH provides
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clinically relevant metrics, such as the DVH – which enables the dose analysis per region of
interest – and other dose points of interest, to obtain a three-dimensional evaluation of the dose
distribution. It consists of an interface that oers a user-friendly way to analyse the plans and the
dose distribution in important structures, giving both quantitative and qualitative information.
Having the necessary les from TPS and ArcCHECK measurements, 3DVH allows to com-
pare the planned dose with the measured dose through DVH and gamma analysis. 3DVH uses
the TPS and ArcCHECK data and creates a new plan perturbed by the errors caused by the
dierences between measured dose and calculated dose. This perturbation is done by using an
algorithm called "Planned Dose Perturbation" (PDP™). Figure 3.17 shows the main steps in 3DVH
analysis.
Figure 3.17: Schematic of the main steps and les and equipment used in 3DVH analysis.
3.8.1 Planned Dose Perturbation Algorithm
The PDP algorithm (Figure 3.18) utilises the measured data and compares it to the planned treat-
ment plan data. It is used in 3DVH to perturb the treatment plan with the errors and dierences
between the planned and measured data, originating a correct dose map with the failed hot and
cold points. This analysis and correction are done voxel-by-voxel. The perturbation allows to
obtain a new and correct dose reconstruction that displays the estimated dose to the patient.
The perturbation can be described as a back-projection of the measured errors into the original
treatment plan, changing each dose voxel of this plan according to the dose dierences detected
between TPS and ArcCHECK [28].
It does not introduce new sources of error. The variations introduced are just the inaccu-
racies existing in the treatment plan that were detected. The plan is altered only if and where
dose dierences are detected. These discrepancies represent the inaccuracies of the TPS dose
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calculation algorithm and of the LINAC. Thus, voxel-by-voxel in both plans are compared, and
the plan is perturbed if some dose dierence was detected with ArcCHECK.
Figure 3.18: Illustration of the PDP algorithm. Both measured and planned dose distribution maps are observed.
They are compared voxel-by-voxel and where a dose dierence is detected, a perturbation is introduced, originating
a new dose map with all these perturbations. Adapted from [100].
The algorithm is explained in detail in Zhen et al. [90]. The absolute dose planes are super-
imposed producing error masks. The absolute dose dierences and local percentage errors are
stored in the error masks, which are afterwards used in the perturbation. The local percentage
dierence (measured-calculated QA dose) error mask is described for the i− th beam as
∆QAdose(i, j)iQAdepth,distance
.
Having both TPS and QA RT plan, the treatment beams are associated with their correspond-
ing QA dose pair. PDP derives the per-voxel dose contribution from each beam. Thus, for the
i − th beam, the contribution by a dose voxel (x, y, z), Doseixyz , is estimated using a physics-
based energy deposition model. Having been portioned into per-beam contributions, each dose
voxel in the 3D grid can be perturbed using the PDP algorithm. The error mask is modied
(depending on the depth in patient/phantom and distance to the voxel from the source) by a
contribution modifying function (CMF) and applied to the dose contribution of the beam i. The
CMF computes the contribution of voxel dose from each beam and modies the errors from
the specic phantom geometry to the patient. For the i − th beam and single voxel (xyz) this
perturbation can be described as:







where PDP ixyz is the perturbation for i beam and single voxel, ∆QAdose(i, j)iQAdepth,distance
is the local percentage dierence, CMF is the contribution modifying function, depending the
depth and distance, QAdose(i, j)iQAdepth,distance is the errors mask, which depends the depth
and distance, and Doseixyz is the dose voxel contribution.
When the total dose perturbation is accumulated over all voxels, it can be used to perturb the







This perturbation can then be applied to the TPS dose grid to generate the new dose grid,
which is corrected by the errors detected corresponding to the dierences between measured
and planned dose distribution [90].
3.8.2 Interface description
As described previously (subsubsectio 3.8.1), 3DVH uses the PDP algorithm to accurately esti-
mate the DVH and other important metrics utilising the ArcCHECK QA data as inputs.
As described in Figure 3.17, the inputs of the 3DVH correspondent to the planned data are 4
DICOM les imported from TPS, RT Plan, RT Structures, CT Images and RT Dose. As to measured
data, 3DVH uses the measured ArcCHECK le (*.acml). The software also uses the RT Dose and
the RT Plan of the ArcCHECK. This allows to perform correspondences between the planned
and measured data, through the coordinates from each TPS and ArcCHECK les, being possible
to estimate the dose on the patient/phantom geometry. The CT images are an optional set of
les, because, as the software compares voxel-by-voxel of the planned and measured plans, it
does not use the CT information, which is the organs density. Thus, this le is just illustrative
for the analysis. However, despite the fact that the CT le is optional, the heterogeneities of the
patient are taken into account, because the planned doses vary based on tissue heterogeneities,
which means, dose deposition is directly related to tissue density. After input insertion, the
calculation is carried out, taking from 3 to 5 minutes, depending on if the plan is an IMRT or a
VMAT planning, respectively.
When calculation ends, the dose distribution analysis can be carried out. It is possible to
perform the gamma analysis, to analyse the ROIs, obtaining their DVH and their statistics, and
to analyse the dose distribution beam by beam.
Figure 3.19 shows an illustration of the 3DVH interface. It is possible to observe the dose
distribution of the individual data (reference or measured) and of the comparison data in the
sagittal, coronal and axial planes of the patient/phantom. On the left-hand side are the structure
colours, quick statistics option and gamma analysis calculation. It is also possible to see the
histogram of the pass and fail points and the number of these points, where the green, blue
and red colours in the histogram indicate matching, underestimated and overestimated doses,
respectively, between treatment plan and measurements. The software provides many analyses.
45
Chapter 3. Methods
In the tabs, it is possible to choose the 3D Dose tab, previously described; DVH analysis, where
both cumulative and dierential DVH for each structure are shown and can be imported and
saved; anatomy structure analysis, where it is possible to do an analysis structure by structure,
obtaining the individual gamma passing rate and pass and fail points to each structure; BEV tab,
where it is possible to analyse each beam and its dose proles; and 4D workspace, which provides
a simulation of the treatment.
Figure 3.19: Illustration of the 3DVH interface and respective analysis options. 3D Dose, DVH, Anatomy Structure
Analysis (ROI’s), BEV and 4D Workspace tabs are presented. The quick statistics section is presented, too. The
example illustrated is from the analysis from a patient’s test.
All the square elds and patient plans were analysed using the 3DVH. As described above,
it was possible to perform the dose distribution analysis, to obtain the gamma analysis and to
obtain the DVH for the main structures and its statics values. as well. Values such as mean dose,
maximum dose, minimum dose and some other dose constraints values, which are specic for
each type of cancer, are the examples of the statics values that can be obtained. Once more, the





The present chapter presents the data analysis and their discussion. Due to the large data ob-
tained, only the most important and relevant data regarding the square eld and patient tests are
presented.
This chapter is divided in two main sections:
• Square Fields Test;
• Patients Test.
Each section contains subsections where gamma analysis and DVH analysis are presented
and discussed for MLC errors and MU errors.
4.1 Square Fields Test
The rst results presented regard a simple case of open square elds without patient hetero-
geneities, that allows theoretical predictions and understanding if the systems are precise on
the data evaluation. This is done comparing the data obtained with predictions previously cal-
culated. Data, with MLC and MU errors and without any error, were acquired by ArcCHECK
and EPID, and analysed using their respective software and 3DVH. The evaluation consisted of
gamma analysis and DVH analysis. Figure 4.1 shows the dose distribution for each square elds
cases, 1 eld (Figure 4.1 (a)), 2 elds (Figure 4.1 (b)) and 4 elds (Figure 4.1 (c)), obtained by 3DVH
and where some dierences are observed between the three plans, related with dose distribution.
The last plans show more homogeneity than the others.
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Figure 4.1: Illustration of the dose distribution in the three cases of the patient ZZZ1 slab phantom: (a) 1 eld, (b) 2
elds and (c) 4 elds, obtained from 3DVH.
4.1.1 Comparison of Gamma Criterion
Gamma analysis is the most common dose evaluation method used. Gamma passing rate, the
percentage of points that satises the condition γ<1, was calculated using specic software cor-
responding to the measurements systems used. SNC (referred as ArcCHECK in the tables and
graphs), 3DVH and PreDose were the software used to obtain gamma analysis for all square elds
plans, in order to test the accuracy of the method and the systems. This analysis was performed
for both MLC and MU errors, using the 3%/3mm criteria, 10% of dose threshold for 2D gamma
analysis performed by SNC and PreDose, and 3%/3mm criteria, 50% of dose threshold for 3D
gamma analysis performed by 3DVH, and 90% as the clinically acceptance threshold. In the case
of MLC errors, 3%/3mm criteria, 3% of dose threshold for PreDose were used, because with 10%
no dierences were observed. The dose thresholds are dierent, because, in 3D gamma analysis
more points are considered comparing with 2D gamma analysis. Consequently, for 3D gamma
analysis, a dose threshold that exclude more points than the threshold used for 2D gamma anal-
ysis is used. Also, the systems of dose measuring and evaluation are dierent and can apply the
gamma analysis algorithm in a dierent way.
MLC Errors
As described previously, the MLC errors change the leaf positions, i.e. they open or close some
millimetres. The errors will inuence the area that is irradiated and the dose that is delivered
to the structure, aecting mainly the edge of the eld. In Table 4.1 the mean of the gamma
passing rates and its specic standard deviation (SD) corresponding to all cases for all MLC errors,
obtained by 3DVH, SNC of ArcCHECK and PreDose are presented.
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Table 4.1: Mean and standard deviation of the Gamma Passing Rate (%γ<1) for the three square elds cases tested
for both systematic (sys) and random (ran) MLC errors.
%γ<1 3DVH ArcCHECK PreDose
Errors (mm) Mean ± SD Mean ± SD Mean ± SD
sys -3 96.6 ± 1.9 90.5 ± 4.3 86.0 ± 4.2
sys -2 97.2 ± 0.7 93.9 ± 3.7 90.3 ± 3.2
sys -1 98.6 ± 0.5 98.2 ± 1.7 95.1 ± 3.0
sys -0.5 98.3 ± 0.9 98.9 ± 1.0 97.2 ± 1.0
0 99.2 ± 0.2 99.2 ± 0.7 98.3 ± 0.1
sys 0.5 98.9 ± 0.5 98.5 ± 1.6 98.2 ± 0.2
sys 1 99.1 ± 0.1 97.6 ± 1.7 97.5 ± 0.5
sys 2 98.7 ± 0.3 92.9 ± 3.6 96.3 ± 0.5
sys 3 98.3 ± 0.9 88.1 ± 5.2 91.6 ± 0.1
ran 1 98.9 ± 0.4 98.2 ± 1.7 97.6 ± 0.8
ran 2 98.5 ± 0.2 96.1 ± 1,9 96.1 ± 0.8
ran 3 98.0 ± 0.4 94.0 ± 2.3 93.5 ± 0.2
ran 4 94.5 ± 4.6 91.2 ± 3.0 90.6 ± 1.8
ran5 94.4 ± 2.6 90.6 ± 3.9 90.2 ± 0.5
Looking at Table 4.1, it is possible to see the eects of the MLC errors in all the plans of the
square elds test, analysing the mean of the %GP for each error. In theory, when leaves open or
close systematically, the evaluation system detects the error, and the gamma value will be worse
than the value obtained for the plan without errors. Thus, the larger the error, the smaller the
gamma passing rate. So, a symmetry between the negative errors and positive errors should be
seen. This happens, because when the leaves are closed or opened the dose distribution along the
structure is dierent comparatively with planned plan. Thus, when the gamma method calculates
the dose dierence in space, this dierence is detected and reected on the gamma passing rate.
For systematic errors, the ArcCHECK results show that the system can detect the errors.
As expected, the larger errors cause more damage than the smaller. A symmetry between the
negative and positive errors is approximately observed. However, the positive errors present
worse gamma passing rate than the negative.
For PreDose data, the system presents more sensibility in the detection of negative errors,
so a great asymmetry between the positive and negative errors is seen. This can be justied
by the dose threshold used, which is related with the maximum planned dose. Despite being
low, which includes the dose values that causes underdose, aecting the %GP obtained, the dose
values obtained when the leaves are opened are outside the threshold, not aecting so much the
%GP. PreDose already detects less dose than it is supposed in the reference situation, possibly the
leaves callibration results in slightly more closed leaves. So, the errors that open the leaves, i.e.
the positive errors, sometimes can correct the dose delivery system and not cause many eects
or even improve the %GP. The %GP from PreDose results are also worse than the ArcCHECK
results, because it takes into account the output variations of the LINAC, unlike ArcCHECK,
which corrects for output variations every day. This eect can also contribute to the asymmetry
seen.
The 3DVH results are very at. They are also very dierent from ArcCHECK results, despite
using ArcCHECK data, not detecting very well the presence of the errors. This can be justied
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by ve reasons:
1. The gamma analysis is not a good and accurate dose distribution evaluation method, which
can be proven if the DVHs of these plans present dierences between measurements and
reference. This evaluation is carried out below;
2. The plans used consist of open square elds, which means, the MLC does not act so much,
comparing with an IMRT plan, for example. Thus, the errors on MLC may not be very
signicant and relevant in these plans;
3. The ArcCHECK software performs a 2D gamma analysis, whereas 3DVH performs a 3D
gamma analysis. In 3D analysis more points will be considered leading to smaller gamma
values;
4. The criteria used. It is complicated to choose the dose threshold. As gamma analysis with
3DVH is considered 3D gamma analysis, it is better to choose a high dose threshold in order
to exclude the larger number of low dose points, which will decrease the %GP. However,
too high thresholds can exclude the points aected by the errors. Also the DTA (3 mm)
criterion used can aect the results, because it is near to the error values introduced;
5. The gaps between the diodes of ArcCHECK. Their distance is 1 cm, which is larger than
the errors introduced.
In the case of random errors, the results are better and the relation between errors and gamma
passing rate is observed for all systems. However, the 3DVH results do not change that much.
The ArcCHECK presents values smaller than 3DVH.
In the following Figure 4.2, this relation between the errors, systematic and random, and
gamma passing rate, and all the eects described are more clearly seen, but now just for the
case of 4 elds, because it is the plan with better homogeneity in the PTV, as it is possible to see
in Figure 4.1. Thus, it can show better the inferences of the MLC errors. It is also possible to
compare the %GP corresponding to PreDose ArcCHECK and 3DVH.
Figure 4.2: Gamma Passing Rates as function of MLC errors for the case of the patient ZZZ1, 4 elds slab phantom
plan for 3%/3mm criteria with 10% dose threshold for ArcCHECK, 3%/3mm criteria with 3% dose threshold for PreDose
and 3%/3mm criteria with 50% dose threshold for 3DVH. The %GP acceptance threshold is 90%. (a) corresponds to
Systematic MLC errors and (b) corresponds to Random MLC errors.
Looking at Figure 4.2 (a) corresponding to systematic errors, it is possible to observe the
relation between errors and gamma passing rate referred above and seen in Table 4.1.
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3DVH does not detect systemaic errors, because the %GP are very similar for all the errors.
ArcCHECK and PreDose show capacity to detect these errors, because high errors show worse
%GP than low errors as expected. However, the %GP are above or very close of the acceptance
criteria and PreDose shows a great asymmetry between the negative and positive errors.
For random errors (Figure 4.2 (b)), all the systems detect their presence, 3DVH included. Once
more, high errors show %GP worse than the low. However, it is dicult to predict the eect of
these errors in the plans, because the leaves moves randomly.
MU Errors
The MU errors aect linearly the dose that is delivered to the patient. Unlike the MLC errors,
MU errors perturb all the eld equally. Table 4.2 presents the mean of gamma passing rate and
its standard deviation obtained by 3DVH, SNC and PreDose for all square elds cases and for
each MU error. The measurement without errors was repeated for the MU error measurements,
because they were done several months after the MLC measurements. The dierence between
the two reference measurements is possibly due to the output variations of the LINAC, for which
PreDose does not correct (but ArcCHECK does), or due to slight changes in LINAC/MLC settings
after the LINAC maintenance.
Table 4.2: Mean and standard deviation of the Gamma Passing Rate (%γ<1) for the three square elds cases tested
for MU errors.
%γ<1 3DVH ArcCHECK PreDose
Errors (%) Mean ± SD Mean ± SD Mean ± SD
-4 79.4 ± 6.2 96.6 ± 1.6 63.1 ± 8.0
-2 98.9 ± 0.4 98.5 ± 1.3 98.1 ± 0.3
0 96.9 ± 1.4 96.0 ± 3.4 97.2 ± 1.1
2 78.7 ± 4.4 83.9 ± 11.3 68.2 ± 6.9
4 40.8 ± 1.3 58.4 ± 29.1 43.1 ± 6.2
From Table 4.2 it is possible to observe that the dose is directly and more aected by the
change of the MUs, because they are directly related with the delivered dose: MU errors aect
the whole eld and MLC errors only aect the edge of the eld.
As expected, the negative errors reduce the dose delivered and the positive errors increase
the dose delivered. As in the MLC errors, the larger the error, the worse the gamma passing rate.
This eect is seen for all systems. However, the positive errors cause more perturbation than the
negative errors, which means, theres is an asymmetry between the negative and positive errors.
Figure 4.3 presents more clearly the relation between the errors and the gamma passing rate
obtained just for the case with 4 elds plans as in the MLC analysis. Once more, it is possible
to compare the data of 3DVH, ArcCHECK and EPID and determine which is more sensitive to
detect the errors.
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Figure 4.3: Gamma Passing Rates as function of MU errors for the case of the patient ZZZ1, 4 elds slab phantom
plan. The analysis was done for 3%/3mm criteria and 10% of dose threshold for PreDose and ArcCHECK; and for
3%/3mm criteria and 50% of dose threshold for 3DVH, with 90% as acceptance threshold
Figure 4.3 shows that, as seen in Table 4.2, the larger errors cause more perturbation than
the smaller and an asymmetry in all systems results is also observed, which means, the positive
errors presented smaller %GP than the negative errors. In this case, a MU increase aects more
the dose delivered than when the MU decreases. This asymmetry shows that the negative error of
-2% is above the acceptance criteria, unlike the positive error of 2%. Taking into account the way
gamma analysis works, the dose thresholds eliminate the smaller dose values of the planned dose
map. Thus, the negative errors, which reduce the dose delivered might not be included in the
analysis as the positive errors will, because they are out of the region analysed by gamma metric,
resulting the asymmetry observed. Again, the asymmetry in the PreDose might be caused by the
output variations of the LINAC, as previously described (subsubsection 4.1.1). The ArcCHECK
and 3DVH results are also dierent due to the dierent threshold used, as mentioned above
(subsubsection 4.1.1).
The gamma passing rate value of 4% was not obtained in 3DVH, because the software crashed:
3DVH cannot handle too large dose deviations (also observed in ArcCHECK results). This is a
limitation of the system.
4.1.2 Analysis of DVHs
DVHs give clinically relevant 3D information of dose distribution in a structure and it is the an-
other option for dose evaluation. 3DVH and pdDVH (referred as EPID in the gures and graphs)
were the software used to calculate DVHs, using data from ArcCHECK and EPID measurements,
respectively.
As many DVHs were obtained, only the relevant ones of MLC errors (systematic of -3 and 3
mm and random of 1 and 5 mm) and of MUs errors (systematic of -4 and 4%) will be presented
in the following sections, and just for the case of 4 elds.
MLC Errors
The eect of MLC errors were detected in the DVH of each structure. These errors aect mainly
the volumes in the DVHs of the structures, so Tables 4.3 and 4.4 present the predictions previously
calculated of the reduction and increase of the volume percentage of each structure for all MLC
systematic errors and for all cases obtained by 3DVH and by pdDVH, respectively.
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The predictions were done just for systematic errors, because the eects of the random errors
are harder to predict, since the leaves move randomly. The systematic errors that aect the
positions of the leaves, closing or opening them symmetrically, will aect mainly the edge of the
elds. Consequently, in cube and cylinder structures more eects are expected than in PTV, for
which any perturbation is not expected. Therefore, the predictions were only calculated for cube
and cylinder. With these predictions is easier to understand if the systems detect accurately the
presence of the errors in the plans.
Table 4.3: Predictions and measurements of the eect of MLC errors in the volume of 50% for the three square elds
cases obtained by 3DVH. The rst column corresponds to the predictions, the second column corresponds to the
dierence between the reference volume (50%) and the measured volume (Vmeas), and the last column shows the
dierence between the second and the rst columns.
Errors (mm) ∆Vpred(%) ∆Vmeas(%) Dierence (%)Cube Cylinder Cube Cylinder Cube Cylinder
Case ZZZ1: Slab Phantom 1 eld plan
-3 -5.0 -6.4 -0.5 -0.3 4.5 6.1
-2 -3.3 -4.2 -0.4 -0.2 2.9 4.0
-1 -1.6 -2.1 -0.3 -0.1 1.3 2.0
-0.5 -0.8 -1.1 -0.3 0.0 0.5 1.1
0 0.0 0.0 0.0 0.0 0.0 0.0
0.5 0.8 1.1 0.0 0.0 -0.8 -1.1
1 1.7 2.1 -0.1 0.1 -1.8 -2.0
2 3.3 4.2 0.0 0.1 -3.3 -4.1
3 5.0 6.4 0.7 0.2 -4.3 -6.2
Case ZZZ1: Slab Phantom 2 elds plan
-3 -5.0 -6.4 0.0 0.0 5.0 6.4
-2 -3.3 -4.2 -0.7 -0.5 2.6 3.7
-1 -1.6 -2.1 -0.4 -0.4 1.2 1.7
-0.5 -0.8 -1.1 -0.3 -0.3 0.5 0.8
0 0.0 0.0 0.0 0.0 0.0 0.0
0.5 0.8 1.1 0.0 0.0 -0.8 -1.1
1 1.7 2.1 0.0 0.4 -1.7 -1.7
2 3.3 4.2 0.0 1.5 -3.3 -2.8
3 5.0 6.4 0.0 1.7 -5.0 -4.7
Case ZZZ1: Slab Phantom 4 elds plan
-3 -5.0 -6.4 -0.1 -0.5 4.9 5.9
-2 -3.3 -4.2 0.0 -0.6 3.3 3.6
-1 -1.6 -2.1 0.0 -0.5 1.6 1.6
-0.5 -0.8 -1.1 0.0 -0.6 0.8 0.5
0 0.0 0.0 0.0 0.0 0.0 0.0
0.5 0.8 1.1 0.0 -0.2 -0.8 -1.3
1 1.7 2.1 0.0 -0.3 -1.7 -2.4
2 3.3 4.2 0.0 0.5 -3.3 -3.7
3 5.0 6.4 0.0 2.0 -5.0 -4.4
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Table 4.4: Predictions and measurements of the eect of MLC errors in the volume of 50% for the three square
elds cases obtained by EPID. The rst column corresponds to the predictions, the second column corresponds to
the dierence between the reference volume (50%) and the measured volume (Vmeas), and the last column shows the
dierence between the second and the rst columns.
Errors (mm) ∆Vpred(%) ∆Vmeas(%) Dierence (%)Cube Cylinder Cube Cylinder Cube Cylinder
Case ZZZ1: Slab Phantom 1 eld plan
-3 -5.0 -6.4 -4.2 -5.6 0.8 0.8
-2 -3.3 -4.2 -3.1 -3.2 0.2 1.0
-1 -1.6 -2.1 -1.4 -1.6 0.2 0.5
-0.5 -0.8 -1.1 -0.4 -1.0 0.4 0.1
0 0.0 0.0 0.0 0.0 0.0 0.0
0.5 0.8 1.1 0.4 1.2 -0.4 0.1
1 1.7 2.1 1.3 2.0 -0.4 -0.1
2 3.3 4.2 2.6 5.1 -0.7 0.9
3 5.0 6.4 6.6 5.2 1.6 -1.2
Case ZZZ1: Slab Phantom 2 elds plan
-3 -5.0 -6.4 -5.0 -7.1 0.0 -0.7
-2 -3.3 -4.2 -2.4 -5.0 0.9 -0.8
-1 -1.6 -2.1 -0.6 -4.1 1.0 -2.0
-0.5 -0.8 -1.1 0.7 -2.5 1.5 -1.4
0 0.0 0.0 0.0 0.0 0.0 0.0
0.5 0.8 1.1 1.0 -0.3 0.2 -1.4
1 1.7 2.1 1.9 0.1 0.2 -2.0
2 3.3 4.2 4.3 3.1 1.0 -1.1
3 5.0 6.4 4.9 4.4 -0.1 -2.0
Case ZZZ1: Slab Phantom 4 elds plan
-3 -5.0 -6.4 -5.7 -6.4 -0.7 0.0
-2 -3.3 -4.2 -5.1 -4.1 -1.8 0.1
-1 -1.6 -2.1 -2.1 -2.2 -0.5 -0.1
-0.5 -0.8 -1.1 -2.4 -1.3 -1.6 -0.2
0 0.0 0.0 0.0 0.0 0.0 0.0
0.5 0.8 +1.1 -0.8 0.1 -1.6 -1.0
1 1.7 2.1 1.0 0.8 -0.7 -1.3
2 3.3 4.2 1.9 4.4 -1.4 0.2
3 5.0 6.4 4.4 5.6 -0.6 -0.8
In Tables 4.3 and 4.4, the predictions are the expected changes in the percentage of the volume
that receives high dose (e.g. >2 Gy, so V(2Gy) in the DVH). For the cube, these predictions
correspond to the size of the MLC error (EMLC ) divided by the length of the cube L (6 cm):
∆Vpred(%) = EMLC/L. (4.1)
So, for a -3 mm MLC error, ∆Vpred(%) = −3/60 = −5%. For the cylinder, we approximated
the prediction by:
∆Vpred(%) = (4/π)× EMLC/L, (4.2)
with L = 6 cm, because we considered the 50% volume for the analysis.
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The following steps were taken to estimate the measured volume ∆Vmeas(%) from the DVHs:
1. We took the dose corresponding to the 50% volume in the reference DVH, i.e. Dref (50%);
2. We determined the volume corresponding to this in the error DVHs, soVmeas(Dref (50%));
3. The measure volume change is then: ∆Vmeas(%) = Vmeas(Dref (50%))− 50%.
The 50% volume was chosen, because it is approximately the volume of cube and cylinder
that is receiving the high dose, as observed in Figure 4.1.
Analysing Tables 4.3 and 4.4, it is possible to see that the 3DVH was not ecient in detecting
the errors. Very little deviation is seen in all the results. This could be explained by ArcCHECK
having a 1 cm gap between the diodes, which size is larger than the error values introduced,
aecting the acquisition and detection of the errors. On the other hand, the pdDVH detects
the errors, and many of the measured results are close to the predictions for all plans and for
both structures. Some dierences between the predictions and measurements observed in EPID
results exist probably because EPID takes into account the output variations of the LINAC.
There is also a lack of correlation between the gamma analysis and the DVHs analysis of
EPID systems. In gamma analysis the system does not detect the presence of the positive errors
very well. However, in DVHs analysis they are detected.
In the following gures (Figures 4.4 to 4.8), these eects are shown on the DVHs, but just for
the systematic errors of -3 and 3 mm and for the random errors of 1 and 5 mm for the plan of
4 elds. We also compared the DVH from Monaco, which is the reference, with the error-free
measured DVHs obtained from 3DVH and pdDVH (Figure 4.4). Figures 4.5 to 4.8 correspond
to the comparison between error-free, measured reference, and measured plans with introduced
errors. The rst evaluation is done to see the usual errors of the clinical system, and the second
evaluation allows to see only the eect of the introduced errors.
Figure 4.4: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, error-free.
The reference data, obtained by Monaco, is compared with the measured data without errors, acquired by the EPID
and ArcCHECK and analysed with pdDVH and 3DVH respectively.
By comparing the EPID and ArcCHECK measurements without errors with the reference
obtained by Monaco, small deviations, mainly in cube and cylinder, are observed. This deviation
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can be related with the variation in the dose delivery, measurement, LINAC output, and planning
systems.
Figure 4.5: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, MLC
Systematic Error of -3 mm analysed with 3DVH and pdDVH. The reference data, i.e. measurements without errors,
is compared with the measured data with MLC systematic errors of -3 mm, acquired by the ArcCHECK and by the
EPID. (a) corresponds to 3DVH analysis and (b) corresponds to pdDVH analysis.
Figure 4.6: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, MLC
Systematic Error of 3 mm analysed with 3DVH and pdDVH. The reference data, i.e. measurements without errors, is
compared with the measured data with MLC systematic errors of 3 mm, acquired by the ArcCHECK and by the EPID.
(a) corresponds to 3DVH analysis and (b) corresponds to pdDVH analysis.
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Figure 4.7: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, MLC
Random Error of 1 mm analysed with 3DVH and pdDVH. The reference data, i.e. measurements without errors, is
compared with the measured data with MLC random errors of 1 mm, acquired by the ArcCHECK and by the EPID.
(a) corresponds to 3DVH analysis and (b) corresponds to pdDVH analysis.
Figure 4.8: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, MLC
Random Error of 5 mm analysed with 3DVH and pdDVH. The reference data, i.e. measurements without errors, is
compared with the measured data with MLC random errors of 5 mm, acquired by the ArcCHECK and by the EPID.
(a) corresponds to 3DVH analysis and (b) corresponds to pdDVH analysis
Looking at the DVHs of PTV, it is possible to see that there is not a great dierence in both
errors cases. When the leaves open, the eld is a bit bigger than PTV, which means, it covers all
the PTV area. So the opening of the leaves will just aect the surrounding PTV area, i.e. the cube
and cylinder structures. When the leaves close, the same eect on the PTV is seen. Despite the
the fact that the leaves closing may aect the area of distribution of the PTV, the margin between
the eld and the PTV can be bigger than the MLC error. Thus, as any signicant dierence is
not detected between the reference and the measured, the leaves may not be closed enough to
include the PTV and may not aect its dose distribution.
In theory, for cube and cylinder structure, the systematic errors will aect how the dose is
delivered to them by reducing or increasing of their volumes. The negative errors will reduce the
space that receives dose, that is, they will reduce the cube and cylinder volumes. The reduction of
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the volume increases with the larger errors. On the other hand, the positive errors will increase
the space that receives the dose, raising the volumes with the larger errors as well. In these
structures, when the dose is delivered, rstly, there is no dose in the volume; after, the dose will
increase until approximately 50% of the volume is irradiated with high dose, because this volume
is in the area irradiated by the eld, as observed in the DVHs and in Figure 4.1 (c). Thus, when
the leaves close, the DVH line moves down, because less volume is aected and when the leaves
open, the DVH line moves up, because more volume is irradiated.
Comparing the DVHs of systematic errors of – 3 mm (Figure 4.5) with the ones of systematic
errors of 3 mm (Figure 4.6) for cube and cylinder, it is possible to see that the eects, described
above, were more detected by the pdDVH, than in the 3DVH, which does not the detect a pres-
ence of the errors, as also previously seen in Tables 4.3 and 4.4. The DVHs of cylinder present
more deviations than the ones obtained for the cube, as expected.
In terms of the random errors, the DVHs presented are for random errors of 1 mm and 5 mm
and it is observed that both systems detect the presence of these errors for all cases. However,
the pdDVH detects better the existence of the errors than 3DVH. It is hard to predict the eect
of these in the volumes, because the leaves move randomly. However, it is possible to claim
that larger errors cause larger consequences of the dose distribution, comparing the DVHs of
random errors of 1 mm (Figure 4.7) with the ones of random errors of 5 mm (Figure 4.8). As in
the systematic errors, it is observed more eects of the errors in the cylinder than in the cube,
principally in the DVH of random error of 5 mm.
DVHs from reference, pdDVH and 3DVH of cube and cylinder present uctuations, related
to dose calculation by the software.
MU Errors
The eect of the MU errors was also analysed by DVH of each structure of each square eld case
1 eld plan, 2 elds plan and 4 elds plan.
As for MLC errors, in Figure 4.9 we compared the Monaco DVH with the ones obtained from
3DVH and pdDVH without errors. Figures 4.10 and 4.11 present the deviations caused by the
MU errors in each structure between the reference, which is the measured data without errors,
and the measured data with errors. As in the MLC errors analysis, having the measured data
without errors as reference allows to take into account only the errors introduced, excluding the
common errors originated by the planning and treatment systems.
Therefore, Figures 4.9 to 4.11 show the eects on the DVHs obtained respectively for without
errors and -4% and 2% (3DVH does no calculate for error of 4%) of MUs errors, just for the case
of 4 elds.
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Figure 4.9: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, error-free.
The reference data, obtained by Monaco, is compared with the measured data without errors, acquired by the EPID
and ArcCHECK and analysed with pdDVH and 3DVH respectively.
Once again, there is no large deviations between the Monaco reference and the measured
plans without errors. Just the common caused by the planning and delivered systems.
Figure 4.10: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, MU Error
of -4% analysed with 3DVH and pdDVH. The reference data, i.e. measurements without errors, is compared with the
measured data with MU errors of -4%, acquired by the ArcCHECK and by the EPID. (a) corresponds to 3DVH analysis
and (b) corresponds to pdDVH analysis.
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Figure 4.11: DVH of the structures, PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan, MU Error
of 2% analysed with 3DVH and pdDVH. The reference data, i.e. measurements without errors, is compared with the
measured data with MU errors of 2%, acquired by the ArcCHECK and by the EPID. (a) corresponds to 3DVH analysis
and (b) corresponds to pdDVH analysis.
It is expected that MU errors aect all the structures in the same way, unlike the MLC errors,
because with MU errors, whole the eld is aected instead of only its edges. Despite half of the
volume of cube and cylinder is aected by the eld, these errors interfere the dose delivered to
each structure, reducing or increasing it.
Observing the PTV DVHs in Figures 4.10 and 4.11, several dierences between the reference
and the measured are seen. The DVHs of the other structures also show variations mainly after
50%, because just approximately 50% of the volume of cube and cylinder structures receives dose,
as seen in Figure4.1 (c). Looking at the negative errors, the moving of the DVH to the left is ob-
served, because, as described above, the negative errors decrease the dose distribution. Looking
at the positive errors, the opposite movement is observed. As expected, the DVH moves to the
right, because the positive errors increase the dose distribution. These movements increase to
the larger errors. Both the systems detect the presence of the errors, presenting many similarities
in the deviations between the reference DVHs and the calculated DVHs.
4.1.3 Comparison of Relative Mean Dose Dierence
In this subsection, the evaluation of the relative mean dose dierence is made. The mean dose
dierence is the dierence between the measured mean dose and the reference mean dose, and
it is an important dose constraint to be evaluated and obtained by DVH analysis. Mean doses
were provided by the 3DVH (ArcCHECK) and by pdDVH (EPID).
MLC Errors
The MLC errors eects are also detected in the mean dose dierence results. Figures 4.12, 4.13
and 4.14 show these eects of systematic (a) and random (b) MLC errors in the case ZZZ1 of 1
eld, 2 elds and 4 elds, respectively, comparing the mean dose dierence detected by 3DVH
and pdDVH.
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Figure 4.12: Relative Mean Dose Dierence of PTV, Cube and Cylinder of the case ZZZ1, 1 eld slab phantom plan.
The data obtained by 3DVH is compared with the data from EPID obtained by pdDVH for the (a) Systematic MLC
Errors and the (b) Random MLC Errors.
Figure 4.13: Relative Mean Dose Dierence of PTV, Cube and Cylinder of the case ZZZ1, 2 elds slab phantom plan.
The data obtained by 3DVH is compared with the data from EPID obtained by pdDVH for the (a) Systematic MLC
Errors and the (b) Random MLC Errors.
Figure 4.14: Relative Mean Dose Dierence of PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan.
The data obtained by 3DVH is compared with the data from EPID obtained by pdDVH for the (a) Systematic MLC
Errors and the (b) Random MLC Errors.
Looking at Figures 4.12 (a), 4.13 (a) and 4.14 (a), the relation between the systematic MLC
errors and the relative mean dose for the three structures, PTV, cube and the cylinder is seen. As
expected, the pdDVH is more sensitive in detecting the errors than 3DVH. As seen previously
in the DVHs, pdDVH can detect the perturbations caused by the MLC, showing now a linear
straight that proves that the larger the errors, the larger the mean dose dierences. On the other
hand, the 3DVH does not detect very well the perturbation caused by the errors, as also seen in
the DVHs. Its curves are very at and near zero for PTV and near approximately ±2% for cube
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and cylinder for all cases. In pdDVH results, more variations in cube and cylinder than in PTV
are observed, as seen in DVH and as expected. The relative mean dose dierence obtained for
PTV are very close to the zero and constant. Comparing the cube and cylinder, the latter is more
aected than the former, because, as previously described, the cylinder has smaller volume than
the cube, so any perturbation on the cylinder causes more damage than in the cube. However,
the dierence is not so high as predicted, mainly for the last case. For the pdDVH results, a
symmetry between the negative and positive errors is seen, that is, the negative errors cause the
same impact than the positive, presenting approximately the same mean dose dierence values.
The negative errors cause underdose, so the mean dose dierence may be negative, and as the
positive errors cause overdose, the mean dose dierence may be positive. In the most results,
mainly in the EPID results, this is conrmed.
Figures 4.12 (b), 4.13 (b) and 4.14 (b) show the relation between the random MLC errors and
the relative mean dose for the three structures for all cases. However, the relation the larger the
error, the larger the perturbations is not observed. Comparing the random error of 1 mm and
random error of 5 mm the relation is observed, as seen in the DVH. However, comparing all the
errors, many uctuations in the mean dose dierence values are seen, which means, it is compli-
cated to understand which interferences the changed of the leaves position causes in the plans,
when they move randomly. Despite larger errors will open more the leaves than the smaller
errors, they also can close them, resulting in an equilibrium, and not causing many changes.
The pdDVH is also more sensitive in detect random MLC errors than 3DVH. In cube and
cylinder, variations are observed, as expected, and in PTV many interferences of the errors are
not observed, mainly in the pdDVH data, as also expected. In 3DVH data there is no signicant
variations in all structures.
Comparing dose dierence analysis with gamma analysis, no correlation between them is
seen. Gamma analysis results present approximately a proportionality between the errors and
the %GP, whereas dose dierence analysis present results with no relation between each other.
MU Errors
The MU error eects can also be detected in the mean dose dierence. It is expected that the
errors increase or decrease the mean dose linearly, so 2 and 4%. In this case the relative mean
dose will also show if the deviations between reference and measured detected by the systems
are equal to the errors introduced.
Figure 4.15, 4.16 and 4.17 show the eects of systematic MU errors described for 1 eld, 2
elds and 4 elds, respectively, comparing the relative mean dose dierence obtained by 3DVH
and pdDVH.
62
4.1. Square Fields Test
Figure 4.15: Relative Mean Dose Dierence of PTV, Cube and Cylinder of the case ZZZ1, 1 eld slab phantom plan.
The data obtained by 3DVH is compared with the data from EPID obtained by pdDVH for the Systematic MU Errors.
Figure 4.16: Relative Mean Dose Dierence of PTV, Cube and Cylinder of the case ZZZ1, 2 elds slab phantom plan.
The data obtained by 3DVH is compared with the data from EPID obtained by pdDVH for the Systematic MU Errors.
Figure 4.17: Relative Mean Dose Dierence of PTV, Cube and Cylinder of the case ZZZ1, 4 elds slab phantom plan.
The data obtained by 3DVH is compared with the data from EPID obtained by pdDVH for the Systematic MU Errors.
Figures 4.15, 4.16 and 4.17, show that the systems detect accurately the errors, because the
relative mean dose obtained for all cases are approximately equal to the error introduction, that
is, the deviations measured were the same as predicted. Thus, the dose value measured is ap-
proximately equal to the dose value predicted.
MU results are better than results of MLC errors. In all plans, linear straights are observed
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for all structures, indicating a proportional relation between the error and the relative mean dose
dierence.
For all the plans, both systems demonstrate capabilities in the detection of the errors and
show results very equals: the relative dose mean presents approximately the same value of the
errors introduced; and the straight obtained are very linear, indicating the proportionality be-
tween the errors and the mean dose dierences. A symmetry is also seen, which means, the
negative errors cause the same eects that the positive errors. However, in the last plan, the
negative errors cause approximately 1% more eects than the positive errors. Probably because
the LINAC may deliver less dose and the high errors compensate this less. Despite some low
deviations, the errors cause the same eects in the three structures for all cases, as expected. In
3DVH analysis, there is no value for the MU error of 4%, because the software did not perform
this calculation.
It is also seen that the negative errors cause underdose, because the relative mean dose dier-
ence results indicate a reduction of 2 and 4%, as expected; and the positive errors cause overdose,
that is, increase the dose delivery, because the relative mean dose dierence results show that
the dose increase 2 and 4%.
Comparing with gamma analysis, a lack of correlation is observed. This analysis shows that
the negative and positive errors cause approximately the same eects in the plans that the posi-
tive errors and the gamma analysis presents that the positive errors cause more eects.
4.2 Patients Test
The second section describes the results relative to the patient tests. After the systems and soft-
ware had been tested using the square elds tests and its predictions, in this section, they will be
evaluated using the patient plans analysis.
In this case, it was not possible to predict quantitatively the results of MLC errors, just the-
oretically, because these cases are IMRT cases. However, for MU errors the predictions were
possible. Once again, the data, with MLC and MU errors, and without errors were previously ac-
quired by ArcCHECK and EPID and analysed with their respective software, SNC and Predose,
and with 3DVH as well.
Gamma analysis and DVH analysis were used for dose distribution evaluation. In this case,
DVH analysis were carried out only with 3DVH. The pdapp just can be used with data of mea-
surements with patient and phantom, as described in the last chapter. For square elds test, it
was possible to perform phantom measurements with errors, because a slab phantom was used.
However, in the case of patients, in vivo measurements with errors were of course not possible.
Thus, the pdDVH did not have the necessary data to create the respective DVHs.
As many data were acquired and it is impossible to show all of them, only one IMRT breast
case and one VMAT prostate case will be analysed in detail in this section.
4.2.1 Comparison of Gamma Criterion
Gamma passing rate, for patient plans, was calculated using PreDose, SNC and 3DVH, the specic
software to analyse the data from EPID and ArcCHECK measurements, respectively in order to
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compare the performance of these software to obtain %GP. The gamma analysis was performed
for both MLC and MU errors tests with the 3%/3mm criteria, 10% of dose threshold for 2D gamma
analysis using PreDose and SNC (referred as ArcCHECK in the tables and graphs), and with the
3%/3mm criteria, 50% of dose threshold for 3D gamma analysis using 3DVH, and with 90% of
acceptance threshold, which is clinically used.
MLC Errors
The MLC errors, which means, errors in the leaf position, aect the dose delivered to the patient.
They increase or decrease the volume aected by the eld and also its delivered dose quantity.
In the case of IMRT and VMAT treatments, the MLC moves while the dose is delivered.
This allows to irradiate only the PTV with high dose, trying to spare as much as possible the
surrounding organs. The planning is also done to avoid damages in these organs. When the
MLC errors are introduced, the leaves open and close, depending on the error. Contrary to what
occurs in square elds tests, dose inside the PTV is aected and it is expected that it is more
aected than the organs at risk. It is also expected that the dose value decreases or increases
with the volumes change, contrary to the square elds, where few changes in the dose delivered
where seen. Once again, the larger (±3, ±2 mm) errors cause more eects than the smaller (±1,
±0.5 mm); and the negatives errors cause underdose, whereas the positive errors cause overdose.
Table 4.5 shows the eects of the MLC errors (systematic of ±3, ±2, ±1, ±0.5 mm and random
of 1, 2, 3, 4 and 5 mm) in the %GP calculated by 3DVH, ArcCHECK and Predose. These data are
the %GP mean, and respectively standard deviation, of the six patient that were tested.
Table 4.5: Mean and standard deviation of the Gamma Passing Rate (%γ<1) for the six patient cases tested for both
systematic (sys) and random (ran) MLC errors.
%γ<1 3DVH ArcCHECK PreDose
Errors (%) Mean ± SD Mean ± SD Mean ± SD
sys -3 46.1 ± 5.2 61.7 ± 9.4 28.6 ± 6.4
sys -2 64.4 ± 8.7 77.3 ± 9.9 58.0 ± 11.2
sys -1 94.7 ± 1.0 92.5 ± 4.7 85.4 ± 12.7
sys -0.5 99.1 ± 0.4 96.4 ± 1.3 93.1 ± 8.0
0 99.7 ± 0.1 97.2 ± 1.4 98.1 ± 2.7
sys 0.5 98.5 ± 0.2 93.4 ± 3.9 98.5 ± 1.0
sys 1 94.6 ± 2.5 83.6 ± 11.4 93.2 ± 4.7
sys 2 53.5 ± 9.8 54.0 ± 24.4 68.8 ± 10.6
sys 3 NA 35.1 ± 15.9 44.1 ± 8.9
ran 1 97.5 ± 3.1 96.3 ± 2.1 97.6 ± 2.9
ran 2 96.4 ± 4.8 95.5 ± 3.0 96.5 ± 3.1
ran 3 96.9 ± 3.9 93.2 ± 4.1 94.8 ± 5.4
ran 4 97.1 ± 3.6 91.7 ± 4.3 92.5 ± 6.8
ran5 92.8 ± 12.5 87.6 ± 4.8 92.0 ± 3.5
Looking at Table 4.5 it is possible to observe the eects of the errors in the %GP calculated
by all the systems, which means, they detect the presence of the both MLC errors. Larger er-
rors cause more eects than the smaller and the %GP without errors is quite good. In random
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errors, their eects are also observed and they increase with the large error as well, but in small
intensity than seen in systematic errors. Their results are above the acceptance threshold, unless
for random error of 5 mm of ArcCHECK measurements (87.6 ± 4.8%), which means, these errors
are less relevant for the treatment. It is not possible to understand if the errors cause underdose
or overdose, just looking at the %GP value. It is necessary to look at the dose maps of the eld
provided by the software used.
Comparing the results obtained by the three systems, it is possible to observe some dier-
ences between 3DVH and ArcCHECK. It can be justied by the explanations referred to in the
Square Fields Test Section (subsubsection 4.1.1), such as for the 3DVH analysis, a dose threshold
dierent from the one used with ArcCHECK analysis was adopted, because 3DVH provides a 3D
gamma analysis and ArcCHECK provides a 2D gamma analysis. The PreDose, in systematic er-
rors, shows more sensibility in negative errors than in positive errors, resulting in an asymmetry,
as seen in square elds errors. Again, it can be related with the threshold chosen and with the
dierent systems used, that can react in a dierent way. Even without errors, PreDose detects
less dose than is planned and it also takes into account the output variations of the LINAC, un-
like ArcCHECK. Therefore, the positive errors may correct the dose delivery system and present
better %GP than negative errors and even the reference situation.
For the systematic error of 3 mm there are no results, because 3DVH did not work for all the
patient plans with large deviations. It did not work for other points in VMAT patient plans, such
as systematic errors of -3, 2, and 3 mm. The 3DVH detects many deviations in VMAT plans, being
more dicult than for the system to calculate VMAT plans than IMRT plans, because the VMAT
is a treatment with more parameters (for instance related with gantry rotation) than IMRT.
Once again, Figures 4.18 and 4.19 are an illustrative example , that is, they show the %GP
obtained with 3DVH, SNC and PreDose just for two patient cases, one IMRT breast patient and
one VMAT prostate patient. Figures 4.18 (a) and 4.19 (a) show the %GP of systematic errors and
Figures 4.18 (b) and 4.19 (b) show the %GP of random errors.
Figure 4.18: Gamma Passing Rates as function of MLC errors for the case of the patient ZZZ28210, 7 elds IMRT
breast plan. The analysis was done for 3%/3mm criteria and 10% of dose threshold for PreDose and ArcCHECK; and
for 3%/3mm criteria and 50% of dose threshold for 3DVH, with 90% as acceptance threshold.
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Figure 4.19: Gamma Passing Rates as function of MLC errors for the case of patient ZZZ1295, 1 arc VMAT prostate
plan. The analysis was done for 3%/3mm criteria and 10% of dose threshold for PreDose and ArcCHECK; and for
3%/3mm criteria and 50% of dose threshold for 3DVH, with 90% as acceptance threshold.
Looking at Figures 4.18 and 4.19, it is possible to see the eect of all MLC errors in the patient
plans through the %GP, as seen in Table 4.5; and again, the consequences of them are seen more
clearly for the larger errors than for the smaller, in both patient plans.
For systematic errors, the ArcCHECK and 3DVH present many similarities in the rst plan
(Figure 4.18 (a)). The PreDose shows once again, more sensibility for the negative errors in
both plans. On the other hand, the ArcCHEK and 3DVH show more sensibility for the positive
errors, which means, the systems show dierent asymmetries. In the second plan (Figure 4.19
(a)), 3DVH could not calculate three plans of the ZZZ1295 patient case, correspondents to the
systematic errors of -3, 2 and 3 mm.
For random errors, the ArcCHECK and PreDose show some similarities for the rst patient
plan (Figure 4.18 (b)). Few signicant eects of the random errors are observed in the rst plan.
Unlike in the last one, in the second plan (Figure 4.19 (b)), more consequences are detected,
mainly with the ArcCHECK. 3DVH does not detect any eects in the second plan, being constant.
Probably, this is due to the fact that for IMRT and VMAT there are so many segments that the
eect of random leaf errors will generally cancel out.
MU Errors
The MU errors cause changes in the patient plans, as well. Modifying the MU value, the dose
delivered to the patient increases or decreases, depending on the error magnitude, which means,
the dose is directly aected. As the MUs are directly related with the dose, all the dose of the
eld is aected, as in the square elds tests.
Table 4.6 shows the eects of the MU errors in six patient elds. It is possible to observe the
mean %GP, and its respective standard deviation, calculated by 3DVH and SNC, using ArcCHECK
measurements and PreDose, using EPID measurements, for each MU error (±4 and ±2%).
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Table 4.6: Mean and standard deviation of the Gamma Passing Rate (%γ<1) for the six patient cases tested for MU
errors.
%γ<1 3DVH ArcCHECK PreDose
Errors (%) Mean ± SD Mean ± SD Mean ± SD
-4 79.6 ± 6.6 93.7 ± 1.5 71.3 ± 7.2
-2 96.1 ± 2.4 97.2 ± 1.4 89.0 ± 7.6
0 98.2 ± 2.2 97.4 ± 1.9 96.7 ± 4.4
2 92.4 ± 6.6 94.8 ± 3.2 97.4 ± 2.8
4 70.5 ± 9.0 87.3 ± 6.8 92.7 ± 8.2
Looking at Table 4.6 and comparing the systems, the positive errors aect more than the
negative errors in 3DVH and ArcCHECK. PreDose keeps to be sensitive to negative errors. Once
again, this is caused by underdose already present in the plan without errors, possibly caused by
the outputs variations of the LINAC and that is taken into account by the PreDose.
Figures 4.20 and 4.21 show the relation between the MU errors and the %GP only for two
examples of the six treatment plans measured previously analysed for MLC errors as well.
Figure 4.20: Gamma Passing Rates as function of Mu errors for the case of the patient ZZZ28210, 7 elds IMRT
breast plan. The analysis was done for 3%/3mm criteria and 10% of dose threshold for PreDose and ArcCHECK; and
for 3%/3mm criteria and 50% of dose threshold for 3DVH, with 90% as acceptance threshold.
Figure 4.21: Gamma Passing Rates as function of MU errors for the case of patient ZZZ1295, 1 arc VMAT prostate
plan. The analysis was done for 3%/3mm criteria and 10% of dose threshold for PreDose and ArcCHECK; and for
3%/3mm criteria and 50% of dose threshold for 3DVH, with 90% as acceptance threshold.
Figures 4.20 and 4.21 show the same eects of the MU errors in the patient plans seen in the
Table 4.6. For both patient plans the errors are detected. Larger errors (±4%) cause more relevant
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eects in the plans. On the other hand, the smaller errors (±2%) do not cause signicant eects,
its %GP are above the acceptance criteria.
In the rst plan, a symmetry is approximately observed for ArcCHECK. 3DVH and the Pre-
Dose show an asymmetry with more deviations detected in negative errors. For the second plan,
ArcCHECK and 3DVH detect more deviations for the positive errors comparatively to the neg-
ative ones and the PreDose detects the opposite.
4.2.2 Analysis of DVHs
DVHs showed to be an accurate and powerful tool for dose evaluation in the square elds test. In
this subsection, its performance in detecting MLC and MU errors will be tested for patient plans.
As described previously, this analysis will be done just using data from 3DVH for two patient
plans, one IMRT breast plan and one VMAT prostate plan, also used in the gamma analysis. For
the rst case, DVHs for PTV and the most important organs at risk, heart and lung (in this case
the left lung, because it is a treatment of a breast left cancer) were obtained. For the second case,
DVHs for PTV, bladder and rectum were also obtained.
MLC Errors
The MLC errors were also detected in the DVH analysis. In Figure 4.22, the comparison between
the planned data, from Monaco and the measured data from ArcCHECK and calculated with
3DVH is observed.
Figures 4.23, 4.24, 4.25 and 4.26 present the DVH for each structure of the plans with errors.
The rst two gures correspond to the IMRT breast plan; and the last two gures correspond to
the VMAT prostate plan.
DVHs of the structures aected by the systematic errors of ± 2 mm for the rst patient plan,
the DVHs of the ones aected by the systematic errors of ± 1 mm for the second patient plan,
and the DVHs of the structures aected by the random errors of 1 and 5 m for both plans will be
presented. The 3DHV did not calculate the DVHs of systematic errors of ± 3 mm for the IMRT
plan and the DVHs of systematic errors ±3 and ± 2 mm for the VMAT plan.
The comparison is done between the reference, which is the error-free data, and the mea-
sured, which is the error data measured with ArcCHECK. It allows to compare the data without
errors with the data with errors and see the deviation between them and what occurs when a
MLC error is introduced. All the data was analysed by the 3DVH.
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Figure 4.22: DVHs of the structures, PTV and organs at risk, of the two patient cases, ZZZ28210 and ZZZ1295,
Error-Free. (a) corresponds to the ZZZ28210, 7 elds IMRT breast plan and (b) corresponds to ZZZ1295, 1 arc VMAT
prostate plan. The reference data, obtained by Monaco, is compared with the measured data without errors acquired
by the ArcCHECK and analysed with 3DVH.
Looking at Figure 4.22, some dierences between the Monaco reference and the measured
are observed. Just small deviations are seen, meanly in the organs art risk. However, they are
not very relevant, which means that the treatment is able to be performed.
Figure 4.23: DVHs of the structures, PTV, Heart and Left Lung, of the patient case ZZZ28210, 7 elds IMRT breast
plan, MLC Systematic Errors. (a) corresponds to systematic errors of -2 mm, and (b) corresponds to systematic errors
of 2 mm. The reference data, i.e. the error-free data, is compared with the measured data with errors acquired by the
ArcCHECK and analysed with 3DVH.
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Figure 4.24: DVHs of the structures, PTV, Heart and Left Lung, of the patient case ZZZ28210, 7 elds IMRT breast
plan, MLC Random Errors. (a) corresponds to random errors of 1 mm, and (b) corresponds to random errors of 5
mm. The reference data, i.e. the error-free data, is compared with the measured data with errors acquired by the
ArcCHECK and analysed with 3DVH.
Figure 4.25: DVHs of the structures, PTV, bladder and rectum, of the patient case ZZZ1295, 1 arc VMAT prostate
plan, MLC Systematic Errors. (a) corresponds to systematic errors of -1 mm, and (b) corresponds to systematic errors
of 1 mm. The reference data, i.e. the error-free data, is compared with the measured data with errors acquired by the
ArcCHECK and analysed with 3DVH.
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Figure 4.26: DVHs of the structures, PTV, Bladder and Rectum, of the patient case ZZZ1295, 1 arc VMAT prostate
plan, MLC Random Errors. (a) corresponds to random errors of 1 mm, and (b) corresponds to random errors of 5
mm. The reference data, i.e. the error-free data, is compared with the measured data with errors acquired by the
ArcCHECK and analysed with 3DVH.
The previous gures (Figures 4.23, 4.24, 4.25 and 4.26) show the expected eects caused by
the introduction of the MLC errors in the patient plans.
In theory, the negative systematic errors cause underdose in the patient, which means, re-
duces the dose delivered. It is reected by the movement of the DVH to the left, comparing with
the reference. On the other hand, the positive systematic errors cause overdose, which means,
increase the dose delivered. This eect is seen by the movement of the DVH to the right, com-
paring with the reference.
Both negative and positive systematic errors cause deviations between the reference and
measured data, and are approximately the same. These deviations are more clear in PTV than
in organs at risk, mainly for the IMRT patient. The deviations caused by the negative errors are
detected, because the maximum dose decreases, so the DVH moves to the left. The eects of the
positive errors increase the dose and the DVH moves to the right, as expected. Unlike gamma
analysis, relevant dierence between the negative and the positive errors is not observed, they
cause approximately the same eect in the plans.
In the case of random errors, any relevant eects are not observed, in both plans. There are
some dierences between the plan with systematic errors of 5 mm and with systematic errors
of 1 mm, but very smooth. Unlike this, the gamma analysis shows some dierences, mainly the
data from SNC. As described in square elds, the random errors do not aect the treatment plans,
because the leaves move in a randomly way and this movement can cancel itself, not aecting
too much the dose in the dierent volumes.
Thus, this analysis allows to understand if the plan is appropriate for the treatment, but
also informs how the errors aect the structures and which ones are aected. DVH gives more
clinically relevant information than gamma analysis. However, this analysis was obtained with
3DVH, which was not eective in detecting the MLC errors in square elds plans, presenting
less accurate results. However, since there is no an alternative measurement or predictions yet,




The perturbations of the MU errors can also be detected by the DVH. Following gures (Figures
4.27, 4.28 and 4.29) show the respective DVH of each structure. The rst two are of breast plan
and the last two are of prostate plan. For both plans, the DVHs of MU errors of ±4 and ±2% will
be analysed.
Figure 4.27 presents the deviations between the reference, data from Monaco, and the mea-
sured, which is the measurements data from the two patient plans without errors. As in the
square elds tests, the reference case was repeated for MU errors, because these measurements
were performed several months later.
Figures 4.28 and 4.29 present the DVH of each structure for the two patient cases in analysis,
allowing the comparison between the reference and the measured. The reference data is the
error-free data and the measured data is the data with the errors measured by the ArcCHECK.
All the data was analysed by the 3DVH.
The rst comparison allows to observe the usual errors of the dose delivery system and the
second comparison allows to take into account only the eect of the errors.
Figure 4.27: DVHs of the structures, PTV and organs at risk, of the two patient cases, ZZZ28210 and ZZZ1295,
Error-Free. (a) corresponds to the ZZZ28210, 7 elds IMRT breast plan and (b) corresponds to ZZZ1295, 1 arc VMAT
prostate plan. The reference data, obtained by Monaco, is compared with the measured data without errors acquired
by the ArcCHECK and analysed with 3DVH.
Looking at Figure 4.27, it is possible to observe some dierences between the reference and
the measured. Small deviations are observed, indicating an underdose, mainly in PTV for the
rst plan and the organs at risk for the VMAT plan. However, they are not very relevant, which
means that the treatment is able to be performed.
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Figure 4.28: DVH of the structures, PTV, Heart and Left Lung, of the patient case ZZZ28210, 7 elds IMRT breast
plan, MU errors. (a) corresponds to MU errors of -4%, and (b) corresponds to MU errors of 4%. The reference data, i.e.
the error-free data, is compared with the measured data with errors acquired by the ArcCHECK and analysed with
3DVH.
Figure 4.29: DVH of the structures, PTV, Bladder and Rectum, of the patient case ZZZ1295, 1 arc VMAT prostate
plan, MU errors. (a) corresponds to MU errors of -4%, and (b) corresponds to MU errors of 4%. The reference data,
the error-free data, is compared with the measured data with errors acquired by the ArcCHECK and analysed with
3DVH.
Unlike the analysis obtained for MLC errors, it is expected that the MU errors results are
more reliable than the MLC errors results, because the square elds tests indicated better results
for the MU errors analysis. It is also expected that the errors aect all the structures in the same
way, because these errors interfere in the dose delivered to the eld, which contains the PTV and
also the organs at risk.
For both plans (Figures 4.28 and 4.29) more deviations between the reference and the mea-
sured in negative errors than in positive errors are observed. However, in the VMAT plan, the
deviations between the reference and measured are more smooth. Figure 4.27 presents an under-
dose, which means the LINAC delivers less dose than it was planned, because the leaves might
be more closed. Therefore, the positive errors can cause less eects that the negative errors.
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The PTV DVH shows more deviations between the reference and the measured than the
other structures, mainly for the rst plan, which was not the expected. The negatives errors
aect the maximum dose detected, which means, it decreases, and the DVH move to the left.
Contrary, the positive errors increase the dose delivered to the patient. Thus, the maximum dose
seen in the DVH will also increase, which means, the DVH moves to the right.
4.2.3 Comparison of Relative Mean Dose Dierence
Analysing the mean dose of the structures is also an important evaluation of the eect of the
errors. It is a helpful analysis obtained from DVH analysis. This consists in analysing the dier-
ence between the measured data (data with errors) and the reference data (error-free data). This
dierence is presented in this subsection as the relative mean dose dierence.
This analysis was performed for the six patient plans, using the 3DVH, for the MLC errors
and MU errors, and, in this subsection, all the results are presented.
MLC Errors
The MLC errors are also detected by analysing the mean dose dierence, because, in the case of
IMRT and VMAT patient plans, the MLC errors aect more the delivered dose to the patient than
in the case of square elds tests.
Figures 4.30 to 4.35 show these eects in PTV and in organs at risk of the six patients analysed.
Figure 4.30: Relative Mean Dose Dierence of PTV, Heart and Left Lung of the case ZZZ28210, 7 elds IMRT breast
plan, MLC Errors, obtained by 3DVH. (a) corresponds to Systematic Errors and (b) corresponds to Random Errors.
The scale of both graphs is dierent.
Figure 4.31: Relative Mean Dose Dierence of PTV, Heart and Right Lung of the case ZZZ8363, 2 arcs VMAT breast
plan, MLC Errors, obtained by 3DVH. (a) corresponds to Systematic Errors and (b) corresponds to Random Errors.
The scale of both graphs is dierent.
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Figure 4.32: Relative Mean Dose Dierence of PTV, Heart and Right Lung of the case ZZZ34486, 7 elds IMRT breast
plan, MLC Errors, obtained by 3DVH. (a) corresponds to Systematic Errors and (b) corresponds to Random Errors.
The scale of both graphs is dierent.
Figure 4.33: Relative Mean Dose Dierence of PTV, Bladder and Rectum of the case ZZZ1295, 1 arc VMAT prostate
plan, MLC Errors, obtained by 3DVH. (a) corresponds to Systematic Errors and (b) corresponds to Random Errors.
The scale of both graphs is dierent.
Figure 4.34: Relative Mean Dose Dierence of PTV, Heart and Left Lung of the case ZZZ29113, 7 elds IMRT breast
plan, MLC Errors, obtained by 3DVH. (a) corresponds to Systematic Errors and (b) corresponds to Random Errors.
The scale of both graphs is dierent.
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Figure 4.35: Relative Mean Dose Dierence of PTV, Heart and Right Lung of the case ZZZ11603, 2 arcs VMAT breast
plan, MLC Errors, obtained by 3DVH. (a) corresponds to Systematic Errors and (b) corresponds to Random Errors.
The scale of both graphs is dierent.
In the systematic errors (Figures 4.30 (a) to 4.35 (a)), for all plans few deviations between PTV
and the other structures are observed. It was expected that the PTV would be most aected by
the errors, but this is not the case.
In all plans, a symmetry is observed, which means, the positive errors cause approximately
the same eects that the negative errors, being the relative mean dose dierences of the structures
approximately the same, in module, for all situations. It is also noticed that dierent plans can
be more or less sensitive to the same systematic leaf error: for ZZZ34486 a 2 mm errors causes a
5-6% mean dose dierence, whereas for ZZZ11603 this would be about 10%. This might be due to
a dierent number of segments (i.e. control points) used in the treatment plans, that is, the more
segments, the larger the dose deviation. 3DVH did not calculate DVH and mean doses for the
systematic errors of 3 mm of IMRT plans and for systematic errors of -3, 2 and 3 mm of VMAT
plans, which is a disadvantage.
Looking at the random error results (Figures 4.30 (b) to 4.35 (b)), there is no relation between
errors and dose for all plans, that is, larger errors do not cause more perturbation than smaller.
Once more, it is proven that these errors do not cause many relevant eects in the treatment
plans. There is also no seen any correlation between the gamma analysis and DVH analysis. In
the gamma analysis, the random errors, mainly the larger, cause the higher perturbations and a
relation between the error and the %GP is seen.
MU Errors
The MU errors also interfere with the dose delivered to the patient. As carried out in square
elds tests, this analysis allows to predict if the system is ecient in detecting the errors. It is
expected that the all mean PTV doses increase or decrease with 2 and 4%, i.e. once again a linear
relation between the MU error and dose. Therefore, the relative dose dierence obtained for the
plans with errors should be the same that the error introduced.
Figures 4.36 to 4.41 show the eects of these errors in the PTV and in the organs at risk of all
patient cases.
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Figure 4.36: Relative Mean Dose Dierence of PTV, Heart and Left Lung of the case ZZZ28210, 7 elds IMRT breast
plan, MU Errors, obtained by 3DVH.
Figure 4.37: Relative Mean Dose Dierence of PTV, Heart and Right Lung of the case ZZZ8363, 2 arcs VMAT breast
plan, MU Errors, obtained by 3DVH.
Figure 4.38: Relative Mean Dose Dierence of PTV, Heart and Right Lung of the case ZZZ34486, 7 elds IMRT breast
plan, MU Errors, obtained by 3DVH.
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Figure 4.39: Absolute Mean Dose Dierence of PTV, Bladder and Rectum of the case ZZZ1295, 1 arc VMAT prostate
plan, MU errors, obtained by 3DVH.
Figure 4.40: Relative Mean Dose Dierence of PTV, Heart and Left Lung of the case ZZZ29113, 7 elds IMRT breast
plan, MU Errors, obtained by 3DVH.
Figure 4.41: Relative Mean Dose Dierence of PTV, Heart and Right Lung of the case ZZZ11603, 2 arcs VMAT breast
plan, MU Errors, obtained by 3DVH.
Looking at Figure 4.39, it is possible to see that the ZZZ1295 patient plan obtained relative
mean dose dierence many close to the MU errors, that is, for this plan the system was eective in
detecting the errors. For this plan is also observed that the structures are aected in the same way
and there is a proportionality between the errors and the relative mean dose dierence, obtaining
more values for the large errors. A symmetry between the negative and positive errors is also
seen, that is both negative and positive errors cause approximately the same perturbations, as
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seen in the DVH. These results do not correlate with the ones obtained in gamma analysis with
PreDose and ArcCHECK, which show an asymmetry between the negative and positive errors.
The other patient plans (Figures 4.36,4.37, 4.38 and 4.41) also present straight lines, that is
the larger the error, the worse the perturbation caused by the errors in the plan. ZZZ28210,
ZZZ8363, ZZZ34486 and ZZZ11693 patient cases show mainly dierences between the structures
in negative errors and also in positive errors, where in the heart, the predictions are not observed,
unlike in the other two structures, where the relative mean dierences are approximately equal
to errors value.
In ZZZ29113 results (Figure 4.40), the predictions are equal to the errors introduced just for
the PTV and heart in the negative errors. The LungL does not suer relevant perturbations. The
fact that the OARs show less steep relation between the error and mean dose probably has to do
with the fact that, in contrast to the PTV, these organs are partly outside the treatment beams:
increasing the MU will therefore not increase the dose in these parts and mean dose increase will
be less than the MU increase.
4.3 Errors
In general, there are some factors that may have aected the results. Beside normal dierences
between the systems that will interfere with the results, there are some external factors that can
also perturb the data such as:
• Interlocks: During the measurements, the LINAC system has many moments that it stops
to deliver dose. This should not aect the treatment, because, after restarting, it delivers all
the dose. However, when it occurs many times during one measurement, it may interfere
in the way how the system acquired the dose.
• Couch interferences: When the dose is delivered between 90° and 270°, the couch is be-
tween the dose source and the dose acquiring system, absorbing some dose.
• Discretization errors: For square elds, in the DVHs, some uctuations are seen, which




As mentioned at the beginning of this study, in the last years, a great growth and development
in the radiotherapy treatment was observed, due to the rapid advance of new, accurate and im-
proved technology. This changed completely the way radiotherapy is planned and performed.
Subsequently, a new way to perform the QA of the treatment had to be conceived, that responded
accurately to all these new enhancements, in order to provide the patient with the best treatment
possible.
The patient-specic QA is an important step during the treatment preparation. It assures the
quality of the treatment, allowing to understand whether or not that treatment is the correct one
to be administered to the patient. It consists of a measurement, which simulates the treatment,
and of a comparison between the plan, performed by the TPS, and the measurement data, in
order to see if there are dierences and errors to overcome.
The dose evaluation in the QA has been performed by the gamma analysis for many years.
This metric uses both dose and spatial criteria to analyse the dose dierences. However, many re-
cent studies have shown incoherencies, poor accuracy, sensitivity, and specicity of this method.
This study, in its turn, also showed this lack of accuracy and relevant information. In eect, the
main goal of this study was to test a new way to perform dose distribution evaluation, DVH,
which might replace the gamma analysis in the QA process.
Our study was carried out at the Champalimaud Foundation, where the QA is performed us-
ing ArcCHECK, as the phantom/dosimeter to acquire dose, and using its specic software, which
applies the gamma analysis to make the dose distribution evaluation. We wanted to implement
a new way to perform dose evaluations using the DVH, a graph that illustrates the dose distri-
bution in a structure per volume, using the 3DVH, a software compatible with ArcCHECK. The
capacity of EPID dosimetry to calculate DVHs was tested too. To test this, MLC errors and MU
errors were introduced in open square elds plans and in patient plans to compare both methods
and both systems.
By comparing the gamma method with the DVH analysis, this study proved that the gamma
analysis is not the best dose evaluation method to use in QA, being limitative and incoherent. It
analyses point to point dose dierence and distance and considers any point, taking into account
the criteria used; and if there are a lot of points in accordance with the gamma criteria chosen
in irrelevant structures, they will aect the evaluation and hide signicant errors in regions
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clinically important or showing errors where they do not really exist. These eects were seen
in the square eld tests and in the patient tests. In the cases where the gamma analysis did
not show errors, when they eectively existed, it was possible to see, by looking at the DVH,
deviations between the reference and the measured data, that is, a lack of correlation between
gamma analysis and DVH analysis was observed. The other problem is related with the small
amount of information provided by this method. It merely gives a value that either accepts or
rejects the treatment, and the software also shows dose proles and a dose map of the eld with
the fail and pass points. However, these points are not placed in and related with the patient CT,
which means, it does not provide information about which regions are aected and it does not
provide information directly related with the dose delivered as well. It is also very complicated
to decide which criteria should be chosen. As mentioned in the Chapter 2 (subsubsection 2.3.2),
3%/3mm criteria and 10% as dose threshold criterion are the most clinically used. However, it
depends on what type of evaluation is required. The dose threshold is related with the maximum
planned dose, instead of the measured dose, because the measured dose has many oscillations.
However, relevant points can be out of the area analysed and are not taken into account, because
only the points that pass the threshold are analysed in the measured plan.
DVH analysis comes as an answer to overcome these disadvantages and limitations. It pro-
vides information about the dose distribution in a structure per volume, i.e. the dose evaluation
is individual and specic to each organ. Both square eld tests and patient tests showed good
results in the DVH analysis. Two correlations were observed: one between the errors and the
expected DVH and the other one between the errors and the dose mean dierences. Thus, it
gives more clinically relevant information to decide whether to accept or reject the plan and the
dose evaluation is signicantly more complete. However, there are some doubts about which
dose constraints should be analysed. There are specic dose constraints for each structure used
in the planning, that can be an option. However, there are external factors, such as the output
variations of the LINAC, that have to be taken into account in the dose constraints, because the
output variations of the LINAC automatically interfere in the treatment.
3DVH was the software tested. It provides both 3D gamma analysis and DVH analysis.
3DVH uses the ArcCHECK measurements, just like its specic software, SNC, which provides
2D gamma analysis. However, 3DVH considers for the analysis more points than the SNC, which
only considers the number of the ArcCHECK diodes. This accounts for some of the dierences
between the 3DVH and the SNC data. 3DVH software is more complete, which means, it pro-
vides many types and options of analysis, such as the dose map of gamma analysis in the CT
of the patient, the individual analysis gamma, the DVHs of each structure and specic statis-
tics. These analyses are very important to see which area is aected by the error. However,
it has some disadvantages, such as, it does not calculate measured plans with many deviations
relatively to the reference. Its analysis is also time-consuming, because it goes beyond a simple
calculation of a number, as done in gamma analysis. In case of square elds, this study showed
smaller sensibility in MLC errors detection, comparing with the EPID, for the square elds test,
i.e. it is questionable if 3DVH can detect all errors. However, its results for MU errors detections
are very good and similar to the EPID results, proving that it can detect these errors. In case of
patients, it shows better results for MLC errors than in case of square elds. However, as some
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lesser results were observed in square elds, the ones obtained for the patients may be not very
reliable. For the MU errors results, in most the plans, it detects the presence of them, i.e. the
results were approximately equal to the predictions, as in square eld tests. For now, 3DVH is
the best solution, because it provides DVH analysis that is better than gamma analysis and it is
a compatible software with ArcCHECK.
Another system was tested in this study, EPID, which has been demonstrating accurate and
sensitive capabilities in dosimetry. In Champalimaud Foundation, its capabilities have been in-
vestigated, in order to be integrated in the QA process. So, EPID measurements and its respective
software were also tested for gamma analysis and for DVHs analysis performance. In both anal-
yses, it showed more sensibility in the detection of the errors. In the case of the square elds for
DVH analysis, it obtained approximately the same results as previously calculated and predicted,
that is, it shows capabilities to measure DVHs. In terms of measurements, EPID has more reso-
lution than the ArcCHECK and is linked to the gantry, perpendicularly positioned relatively of
the dose source, which means that it follows the dose source during all the measurement, acquir-
ing dose in all angles and its set-up is not time-consuming. ArcCHECK presents as well a great
geometry for accurately acquiring dose in all angles. However, there are diodes overlapping and
gaps between the diodes where dose is not measured. This aects the MLC errors detection,
because the gaps size (1 cm) is larger than the introduced errors, this being the main cause of
some lesser results of 3DVH. ArcCHECK is a good option to perform the QA, but EPID proved
to be better.
For now, it is necessary to nd the dose constraints for the DVHs analysis, understand how
to perform this analysis and how the QA routine will be done with this new tool. It is also
important to trust this the new software, 3DVH, which shows many advantages in the dose
distribution evaluation, in order to try to implement it clinically. To this end, another test could
be performed: creating patient plans in the slab phantom to compare the DVH analysis of 3DVH
with the one of EPID. It allows to understand if the deviations detected by the 3DVH in the patient
plans are relevant and real, comparing with the EPID that has shown better results, mainly in
MLC errors. The comparison between the DVH analysis of patient plans from EPID with the one
from 3DVH was not performed in this study, and it would be interesting to see if EPID works
accurately in analysing these plans as well.
In sum, the DVH analysis proved to be an important and accurate analysis for the dose eval-
uation during the specic-patient QA. It was seen that 3DVH has the capabilities to execute this
analysis. In addition to this, it was proven that EPID dosimetry is also a good, if not a better,
option to be implemented, due to its precise capabilities to perform DVHs analysis, requiring
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